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Abstract 
Abdominal aortic aneurysm (AAA) disease is characterised by an 
asymptomatic, permanent, focal dilatation of the abdominal aorta 
progressing towards rupture, which confers significant mortality. Patient 
management and surgical decisions currently rely on aortic diameter 
measurements via abdominal ultrasound screening. However, AAA rupture 
can occur at small diameters or may never occur at large diameters. 
Therefore, there is a need to develop molecular imaging-based biomarkers 
independent of aneurysm diameter that may help stratify patients with early-
stage AAA to reduced surveillance. AAA uptake of [18F]fluorodeoxyglucose 
on positron emission tomography (PET) has been demonstrated previously; 
however, its glucose-dependent uptake may overlook other key 
mechanisms. The cell proliferation marker [18F]fluorothymidine ([18F]FLT) is 
primarily used in tumour imaging. The aim of the overall study for this thesis 
was to explore the feasibility of [18F]FLT PET / computed tomography (CT) to 
visualise and quantify AAA in the angiotensin II (AngII)-infused mouse 
model. The experiments presented in this thesis revealed increased uptake 
of [18F]FLT in the 14-day AngII AAA model than in saline controls, followed 
by a decrease in this uptake at 28 days. Moreover, in line with the in vivo 
PET/CT findings, Western blotting of aortic tissue revealed increased levels 
of thymidine kinase-1 (the substrate of [18F]FLT) and nucleoside transporters 
in the 14-day AngII AAA model than in saline controls, followed by 
decreased expression levels at 28 days. A pilot experiment further 
demonstrated that [18F]FLT PET/CT could be used to detect an early 
therapeutic response to oral imatinib treatment in the AngII AAA model. 
Therefore, [18F]FLT PET/CT may be a feasible modality to detect and 
quantify cell proliferation in the AngII AAA murine model. The findings of this 
thesis are encouraging for the application of [18F]FLT PET/CT in patients 
with small AAA. 
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Preface 
Historical context: The mystery that outsmarted Albert 
Einstein 
Albert Einstein, one of the most influential scientists of the 20th century and 
father of the revolutionary Theory of Relativity, was faced with a puzzle that 
was daunting even for someone of his calibre. For years, he had suffered 
from attacks of upper abdominal pain every 2–3 months, each lasting for 2–3 
days and often accompanied by bouts of vomiting. He was nearing 70 years 
of age, slightly overweight, and a regular pipe smoker; the rest of his history 
was unremarkable. In late 1948, he finally consulted with Dr Rudolph 
Nissen, a thoracic surgeon at the Brooklyn Jewish Hospital. Physical 
examination revealed a pulsating mass deep in his abdomen. Further 
assessment revealed a weakened, dilated span of the largest artery in the 
body: the aorta. Einstein, the brilliant theoretical physicist, was diagnosed 
with an abdominal aortic aneurysm (AAA). 
 Patients with AAA exhibit a focal ballooning of the abdominal portion 
of the aorta. Individuals who are male, are older than 60 years of age, are 
former or current smokers, have a positive familial history, and have high 
blood pressure fulfil the criteria for being at risk of developing AAA. Most 
cases of AAA remain clinically silent until they progress to a more critical 
stage. Aneurysms grow in size over time and eventually rupture, an event 
that causes profound internal bleeding and inevitable patient death 
(Sakalihasan et al., 2018). Nissen aimed to prevent Einstein’s aneurysm 
from rupturing by wrapping the aneurysm of arguably the most intelligent 
man in the world with a common kitchen item: cellophane. This was a 
ground-breaking procedure implemented in 1948, with the rationale that the 
tightly wrapped cellophane would elicit an immune response to the ‘foreign 
body’. Immune cells would tackle the perceived intruder and, by proximity, 
the cells within the wrapped aortic section, which would trigger a full-blown 
immune attack and eventually narrow the aneurysmal aorta. This pioneering 
measure was an ingenious approach at the time, as a bit of cellophane 
sufficed to keep Einstein symptom-free and able to continue with his physics 
research for roughly 7 years. Currently, the wrapping of cellophane has been 
replaced by the more sophisticated removal of the aneurysmal section and 
insertion of a specialised graft to conjoin the gap.  
 In 1955, however, Einstein developed severe abdominal and back 
pain, which are also common acute signs of worsening prognosis, as the 
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cellophane was no longer sufficient to restrict the AAA expansion. At this 
point, he was offered another exploratory surgery that might have added a 
few more years to his life. Aneurysms tend to exhibit prolonged courses of 
progression and can be detected well before they rupture. As the risk of AAA 
rupture and internal bleeding increases with aortic size, early AAA detection 
combined with the ability to stratify patients according to rupture risk is 
crucial. Einstein, who at 76 years of age was content with his long and 
gratifying life, refused the additional life-extending surgery, as he parted with 
the famous wise words, ‘I have done my share, it is time to go. I will do it 
elegantly’ (Zimmermann, 2018).  
Motivation 
AAA has long represented a significant clinical burden, owing to the lack of 
effective risk stratification methods and inability to confidently predict the 
incidence of post-surgical complications. The selection of patients to 
undergo surgical intervention is based on aneurysm size and growth rate 
revealed through abdominal ultrasound scanning (USS)-based screening, 
which is currently implemented in the UK for all men older than 65 years of 
age. However, the traditional anatomy-based screening of AAA fails to 
comprehensively elucidate the risk of aneurysm rupture and predisposition 
to surgery-related complications. Molecular imaging of biological events that 
are involved in AAA formation and rupture is likely to improve patient risk 
stratification and help distinguish between patients who would benefit from 
different therapies by dividing them into ‘watchful waiting’ and ‘imminent 
surgery’ groups, for example, eventually resulting in decreased AAA 
morbidity and mortality. 
 This thesis focusses on the novel application of positron emission 
tomography (PET) / computed tomography (CT) with a radiotracer that is 
predominantly used for tumour imaging: [18F]fluorothymidine ([18F]FLT). 
[18F]FLT is a marker of cell proliferation, thus being a suitable indicator of 
cancer progression. Meanwhile, there is emerging evidence of early-stage 
cell proliferation in the pathophysiology of AAA that proceeds to a late-stage 
process characterised by apoptosis and senescence; therefore, cell 
proliferation is an interesting molecular target for imaging. The overarching 
emphasis in this thesis is placed on assessing the feasibility of using 
[18F]FLT PET/CT to visualise and quantify cell proliferation in a classical 
murine model of AAA.  
Thesis overview 
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Four main chapters comprise this thesis to convey the journey of 
implementing [18F]FLT PET/CT in a AAA mouse model. An overview of the 
chapters is presented below. 
Chapter 1 (Background): This chapter provides a comprehensive 
introduction to the basic concepts underlying AAA in terms of its 
pathophysiology and clinical issues. Clinical and preclinical imaging is 
discussed, followed by a particular focus on PET and radionuclide-based 
tracers. This then sets the stage for the introduction of the overall 
hypothesis, aim, and research objectives of the thesis. 
Chapter 2 (Methods): The methods implemented for the experiments 
described in this thesis and their rationale are outlined in this chapter. 
Descriptions of the different mouse models used in the overall study are 
provided, following by details of the methodologies implemented, including 
histological staining, in vivo USS and PET/CT, ex vivo gamma counting and 
autoradiography, and Western blotting. The methods adopted for statistical 
analyses are also outlined.  
Chapter 3 (Results): All the key findings of the overall research are 
systematically reported in this chapter. The presence of cell proliferation in 
different murine models of AAA was first investigated to prioritise a model to 
implement for the in vivo PET/CT experiments. The uptake of the gold-
standard radiotracer [18F]fluorodeoxyglucose ([18F]FDG) was first tested, 
followed by [18F]FLT uptake in healthy control mice, before finally assessing 
[18F]FLT uptake in AAA models. The results of a pilot therapeutic-based 
PET/CT study are also presented in this chapter. 
Chapter 4 (Discussion): A general discussion of the key results arising from 
the overall research is included in this chapter, starting with the histological 
evidence of cell proliferation in AAA and expression of key players in the 
[18F]FLT mechanistic pathway. A comprehensive discussion of [18F]FLT 
uptake in the AngII AAA model and PET image analysis is then provided, 
followed by a discussion of anti-proliferative treatment for AAA. The chapter 
then ends with potential future directions of AAA research and concluding 
thoughts. 
Key contributions 
The following are the specific achievements of this thesis: 
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(i) [18F]FLT uptake on in vivo PET/CT and ex vivo gamma counting has been 
characterised for the first time in a classical murine model of AAA, revealing 
a peak in abdominal aortic uptake in the early stage of the disease; 
(ii) the expression levels of key players in the thymidine mechanistic 
pathway were found to be increased in the early stage of AAA, mirroring the 
pattern of [18F]FLT uptake; 
(iii) [18F]FLT PET/CT was identified as a feasible modality to evaluate the 
response to an anti-proliferative agent in a classical murine model of AAA, a 
finding that would benefit from further validation using large sample sizes; 
and 
(iv) an optimised quantification approach was identified for PET image 
analysis, which may have implications for future analyses of PET data. 
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Chapter 1 Background 
This chapter presents a general introduction to aneurysms, before narrowing 
down to aortic aneurysms. A brief comparison between AAA and thoracic 
aortic aneurysms (TAA) is presented in terms of cellular biology and 
genetics. The spotlight then turns to AAA with a focus on important clinical 
aspects related to screening and diagnosis, along with pathophysiological 
and biomechanical characteristics that contribute to AAA formation. Next, 
the importance of preclinical imaging is highlighted with a brief overview of 
different imaging modalities in the context of AAA, followed by a discussion 
of PET and quantitative image analysis. Finally, [18F]-based PET 
radiotracers are discussed with a particular emphasis on [18F]FLT, in 
addition to literature focussing on recent studies investigating AAA using 
PET. Finally, the overall hypothesis, aim, and research objectives of the 
thesis are presented. 
1.1 Aneurysms 
The word ‘aneurysm’ is derived from the Greek word aneurysma, meaning 
dilation. An aneurysm is a focal dilation of a blood vessel to greater than 1.5 
times its normal size, predominantly due to weakening of the arterial wall. 
Aneurysms can develop in various arteries throughout the body, with the 
most common sites being branches of the Circle of Willis in the brain and the 
aorta. Aneurysms that develop in the cerebral vasculature are referred to as 
intracranial aneurysms. Rupture of these aneurysms commonly causes 
subarachnoid haemorrhage, a severe type of stroke that involves bleeding 
into the area between the arachnoid membrane and pia mater surrounding 
the brain (Keedy, 2006). Meanwhile, the aorta is the largest artery in the 
body that originates in the left ventricle of the heart and passes through the 
chest and abdomen. AAA, which develops in the part of the aorta that 
passes through the abdominal cavity, is the most common type of aortic 
aneurysm. TAA develops in the part of the aorta that passes through the 
chest (Harris et al., 2016). Aneurysms can also occur in peripheral arteries, 
which are less likely to rupture than aortic aneurysms. Some examples 
include aneurysms of the popliteal artery in the leg behind the knee, carotid 
artery in the neck, splenic artery near the spleen, femoral artery in the groin, 
and mesenteric artery that supplies the intestines.  
1.2 Aortic aneurysms 
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Aortic aneurysms can occur at different sites, which are named accordingly, 
such as ascending aortic aneurysms, aortic arch aneurysms, descending 
TAA, thoracoabdominal aortic aneurysms, and AAA (Figure 1.1). Increasing 
evidence suggests that TAA and AAA are unique pathophysiological entities 
with different characteristics (Ruddy et al., 2008, Kuivaniemi et al., 2015). 
The aorta contains intimal, medial, and adventitial layers; however, these 
layers in the thoracic aorta are structurally different from those in the 
abdominal aorta. Essential components of the medial layer include lamellar 
units, which are unique fibromuscular layers of smooth muscle cells (SMCs) 
enveloped by structural proteins such as collagen, elastin, and 
proteoglycans that facilitate the dispersal of stress and supply elasticity. The 
media of the thoracic aorta contains approximately 60 lamellar units that are 
further distributed across avascular and vascular regions. Meanwhile, the 
abdominal aorta contains roughly 30 lamellar units and is exclusively 
avascular (Kuivaniemi et al., 2015). Variations in the delivery of oxygen, 
growth factors, and nutrients to cells of the thoracic and abdominal aortic 
media are likely to play a role in the variations observed in vascular 
remodelling between the two aortic regions. The smaller number of lamellar 
units, avascular form, and thinner wall of the abdominal aorta in comparison 
to the thoracic aorta may also contribute to the greater incidence of AAA 
than of TAA (Guo et al., 2006, Ruddy et al., 2008).  
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Figure 1.1 Anatomy of the aorta.  
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The role of genetics in TAA and AAA is well studied. Many cases of TAA are 
associated with genetic syndromes, such as Marfan syndrome due to 
mutations in fibrillin-1, Ehlers–Danlos syndrome caused by mutations in type 
III collagen, and Loeys–Dietz syndrome caused by mutations in transforming 
growth factor-β receptors 1 and 2 (Elefteriades and Pomianowski, 2013). 
TAA may also occur in individuals with genetic predispositions in the form of 
familial TAA and aortic dissection, the risk of which is also increased with 
mutations in vascular smooth muscle cell (VSMC) contractile proteins 
(Pannu et al., 2006, Guo et al., 2007). Meanwhile, specific mutations in 
relation to genetic predispositions in AAA are not entirely clear, although 
AAA is associated with a first-degree familial history of aneurysmal disease 
(Guo et al., 2006, Harris et al., 2016). A meta-genome-wide association 
study by Jones et al., to which Leeds contributed more than 500 patient 
samples, verified the roles of a number of risk loci that appear to exhibit 
particular specificity for AAA: BCAR3, SORT1, NOTCH2, TDRD10, UBE2W, 
CDKN2B-AS1/ANRIL, LRP1, NAB2, FGF9, and PLTP (Jones et al., 2017). 
The formation of both TAA and AAA are complex processes resulting from 
the interaction of various contributory factors. Whilst TAA is primarily a 
genetic condition with a single gene mutation resulting in aneurysm 
development in a specific patient, AAA is a more degenerative disease of 
older age with a polygenic footprint of an array of susceptibility genes. More 
studies are needed to build a more complete understanding of the 
differences in aetiologies and pathogeneses of aortic aneurysms. The 
remainder of this chapter lays the foundation for the AAA-centred 
experiments presented in this thesis, which were conducted to elucidate the 
molecular mechanisms of AAA.  
1.3 Abdominal aortic aneurysms 
1.3.1 Clinical features 
AAA disease is characterised by localised dilatation of the abdominal aorta 
from a normal diameter of approximately 10–20 mm to an aneurysmal 
diameter of 30 mm or greater. AAA is asymptomatic, yet simultaneously 
progressive towards rupture and profound internal bleeding, resulting in a 
high mortality rate in the range of 59–83% for patients with ruptured AAA 
who either cannot make it to the hospital in time or do not undergo surgery 
(Blanchard et al., 2000, National Institute for Health and Clinical Excellence, 
2008, Kumar et al., 2017). From 2005 to 2012, 39,740 aneurysm-associated 
deaths occurred in England (Karthikesalingam et al., 2016). Ruptured 
11 
aneurysms manifest with severe abdominal or back pain, hypotension, and 
shock. Various environmental and genetic risk factors contribute to the 
development and progression of AAA; the predominant risk factors of AAA 
include increased age, male gender, cigarette smoking, and elevated 
diastolic blood pressure (Blanchard et al., 2000, Thompson et al., 2002, 
Sakalihasan et al., 2018). Meanwhile, the risk of aneurysm rupture may be 
enhanced by rapid aortic expansion, female gender, cigarette smoking, and 
hypertension. Although it is suggested that patients with AAA undergo 
interventions that lower cardiovascular risk, in addition to smoking cessation, 
there remains limited evidence that these approaches reduce AAA-
associated morbidity and mortality (Toczek et al., 2016). Therefore, there is 
an unmet clinical need for interventions that specifically target AAA. 
1.3.2 Screening and monitoring 
Early-stage AAA does not manifest with any apparent signs or symptoms; 
therefore, it is usually diagnosed incidentally during unrelated medical 
check-ups or more recently through screening programmes, which have 
been formally launched in several countries including the US, the UK, and 
Sweden (Davis et al., 2013, Guirguis-Blake et al., 2014, Johansson et al., 
2015, Zarrouk et al., 2016). The National Health Service (NHS) AAA 
Screening Programme was fully implemented in 2013 in England to offer 
routine USS-based screening for all men aged older than 65 years. This 
programme was established based on the results of the UK Multicentre 
Aneurysm Screening Study (MASS), which demonstrated a nearly 50% 
reduction in AAA-related mortality risk after 13 years in men invited for 
screening compared with that in men who did not undergo screening (0.66% 
vs. 1.12%). The UK MASS further showed that this reduction was associated 
with an incremental cost-effectiveness ratio of £7600 per quality-adjusted life 
years (QALYs) gained at 10 years (Ashton et al., 2002, Thompson et al., 
2012). 
Cost-effectiveness is an important aspect to consider when implementing 
AAA screening programmes in the general population. If health benefits are 
assessed in terms of QALYs, then the cost-effectiveness of AAA screening 
may be evaluated based on the incremental cost-effectiveness ratio (ICER) 
of screening vs. no screening (Equation 1.1): 
𝐼𝐶𝐸𝑅 =
𝑐𝑜𝑠𝑡𝑠𝑐𝑟𝑒𝑒𝑛𝑖𝑛𝑔 − 𝑐𝑜𝑠𝑡𝑛𝑜_𝑠𝑐𝑟𝑒𝑒𝑛𝑖𝑛𝑔
𝑄𝐴𝐿𝑌𝑠𝑠𝑐𝑟𝑒𝑒𝑛𝑖𝑛𝑔 − 𝑄𝐴𝐿𝑌𝑠𝑛𝑜_𝑠𝑐𝑟𝑒𝑒𝑛𝑖𝑛𝑔
 
Equation 1.1 Incremental cost-effectiveness ratio 
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Based on economic modelling that incorporates AAA prevalence, size 
distribution at initial screening, and screening attendance to determine the 
ICER, AAA USS-based screening implemented in England for men aged 65 
years and older remains highly cost-effective per QALYs gained (Glover et 
al., 2014, Zarrouk et al., 2016). The gain in QALYs is attributed to screening 
being used to detect when AAA reaches the intervention threshold, i.e. the 
point at which the risk of intervention no longer outweighs the risks of 
intervention.  
1.3.3 Intervention thresholds 
AAA is currently managed through careful monitoring of aortic diameter 
based on USS; the frequency of surveillance in patients reflects AAA size. 
Small AAA (30–49 mm in diameter) typically grow at a rate of 2–4 mm/year; 
this growth rate increases to >7 mm/year beyond a diameter of 55 mm 
(Vega de Céniga et al., 2006, Huang et al., 2019). Patients with small AAA 
are regularly monitored (e.g. annually for AAA with diameters of 30–45 mm 
and every 3 months for AAA with diameters of 45–55 mm) until the (a) 
diameter exceeds 55 mm or (b) growth rate exceeds 10 mm/year; when 
either of these criteria are fulfilled, patients are referred for surgery. 
International guidelines, however, suggest a diameter threshold of 50 mm in 
women, based on the observations that women have a three-fold higher risk 
of AAA rupture than men and the mean aortic diameter preceding AAA 
rupture is larger in men than in women (Powell et al., 1996, Brown and 
Powell, 1999, Moxon et al., 2010). Aortic size has been shown to be 
correlated with rupture risk. Oliver-Williams et al. recently reported rupture 
risks of less than 0.5% for men with AAA less than 55 mm in diameter (Table 
1.1) (Oliver-Williams et al., 2019).  
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Table 1.1 Estimated annual risk of AAA rupture. Sources: (Kent, 2014, 
Ullery et al., 2018) 
 
AAA Diameter (mm) Rupture Risk (%/y) 
30–44 0.03 
45–49 <0.3 
50–54 0.40 
55–59 <10 
60–69 10–20 
70–79 20–40 
≥80 30–50 
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Furthermore, for each 5-mm increase in AAA diameter, the mean aortic 
growth rate increases by 0.59 mm/y, with an increase in the AAA rupture 
rate by a factor of 1.91. These values work out to more than 7 years of 
surveillance for a 30-mm AAA and about 8 months of surveillance for a 50-
mm AAA to reduce the risk of AAA exceeding 55 mm in diameter to less 
than 10% in men (RESCAN Collaborators et al., 2013). These results 
indicate that a watchful waiting period of several years is suitable for patients 
with small AAA. Surgical intervention is offered once the aortic diameter 
exceeds 55 mm; adoption of this threshold in the clinic is supported by 
evidence from four different trials (the UKSAT, ADAM, CAESAR, and 
PIVOTAL studies) that demonstrates no significant advantage to early 
surgical intervention for small AAA (Filardo et al., 2015). Whether non-
surgical options may be effective for small AAA is currently unknown. 
The important point to note here is that although there is extensive ongoing 
research to establish more reliable and informative risk markers of AAA, the 
only indicator that is used consistently in the clinic is aortic size. This is the 
simplest and most convenient parameter to extract using USS, but may not 
always accurately reflect prognosis, as small AAA have been reported to 
rupture, whilst large AAA have been reported as remaining stable 
(McGloughlin and Doyle, 2010). Some other proposed risk markers that are 
under ongoing validation are aortic wall stress, the finite element analysis 
rupture index, vessel asymmetry, intraluminal thrombus growth, and the 
rupture potential index; in addition, aortic wall stress and intraluminal thrombi 
have been demonstrated to be independent of aortic diameter, hence 
justifying the notion of utilising more than aortic size alone when evaluating 
AAA rupture risk (Stenbaek et al., 2000, Fillinger et al., 2003, Vande Geest 
et al., 2006, Doyle et al., 2009, Zhu et al., 2020). However, these potential 
markers require substantial investigation before being introduced into clinical 
practice.  
1.3.4 Interventions 
Surgical intervention for AAA is currently offered once the aortic diameter 
reaches 55 mm in maximal diameter. The exact timing of surgery is often 
difficult to determine due to the risks associated with AAA progression and 
surgery invasiveness; the 55-mm aortic diameter acts as a threshold at 
which point the annual risk of AAA rupture is similar to the mortality risk of 
surgery (Moxon et al., 2010, Cafueri et al., 2012). It is well established that 
the low rupture rate in small aneurysms and risks correlated with surgical 
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intervention do not sufficiently justify routine repair of small AAA (Filardo et 
al., 2015, Chuen and Theivendran, 2018). 
The two main types of surgical intervention currently offered are open 
aneurysm repair (OAR) and endovascular aneurysm repair (EVAR). OAR 
has been performed since the mid-1950s and involves making a large 
abdominal incision to expose the abdominal aorta, followed by insertion of a 
synthetic graft that is sewn in place to replace the weakened portion of the 
aorta. OAR is a highly invasive procedure that confers considerable mortality 
and morbidity risks due to which many patients are denied for surgery. On 
the other hand, EVAR involves making an incision in the groin area, followed 
by insertion of a collapsed synthetic graft through the femoral artery that is 
opened inside the aneurysm with X-ray guidance and fixed in place with a 
stent. EVAR was introduced with the promise of being a solution to the 
pitfalls of OAR and comes with the advantages of requiring smaller incisions, 
conferring fewer perioperative complications, being less painful for the 
patient, being associated with lower mortality and morbidity rates, and 
requiring less hospitalisation in comparison to OAR (Greenhalgh, 2004, 
Prinssen et al., 2004, Kontopodis et al., 2020). However, EVAR is also 
reported to be associated with an increased frequency of readmissions due 
to the lack of long-term durability (Sandford et al., 2014). The short-term (i.e. 
0–6 months following surgery) survival benefits of EVAR compared to those 
of OAR (4.6 vs. 10.0%/person-years) appear to be reduced beyond 8 years 
following surgery (1.3 vs. 0.2%/person-years) (Patel et al., 2016). The 
National Institute for Health and Care Excellence guidelines have previously 
suggested removing EVAR as an option from the NHS for elective cases 
(National Institute for Health and Clinical Excellence, 2018); however, these 
have since been updated to include EVAR in cases wherein OAR is 
contraindicated (National Institute for Health and Clinical Excellence, 2020). 
Nonetheless, the implementation of EVAR in AAA management remains 
controversial, and its effects on the long-term prognosis of patients with AAA 
remain under scrutiny to facilitate improvements in the procedure.  
1.3.5 AAA development 
The pathophysiology of AAA involves active and dynamic pathological 
remodelling of the connective tissue within the aortic wall; however, the 
exact sequence of events remains largely unclear (Davies, 1998, Kuivaniemi 
et al., 2015, Petsophonsakul et al., 2019). During early-stage AAA formation, 
changes in haemodynamic stress and aortic wall elasticity occur, likely in 
response to one or more of the causal risk factors described in section 1.3.1, 
16 
such as cigarette smoking and increased diastolic blood pressure. 
Macrophages also infiltrate the vessel wall due to increased oxidative stress, 
leading to protease secretion that deteriorates the vessel wall via 
extracellular matrix (ECM) degradation; the upregulation of pro-inflammatory 
cytokines and chemokines further contributes to compromised aortic wall 
integrity (Henderson et al., 1999, Thompson et al., 2002, Cafueri et al., 
2012, Kuivaniemi et al., 2015, Sun et al., 2018). Although extensive research 
has focussed on the role of inflammation in AAA, inflammatory mechanisms 
only account for part of the overall story (Patel et al., 1996). This is further 
evidenced by the lack of definitive findings of anti-inflammatory therapy 
attenuating AAA growth, with some enhancing AAA growth (Yoshimura et 
al., 2018, Tedjawirja and de Waard, 2019). 
It is increasingly recognised that the proliferation of VSMCs, which reside in 
the tunica media and are responsible for controlling blood pressure and flow 
distribution, contributes to AAA development (Owens et al., 2004, Chasman 
and Lawler, 2017). An early study in this field demonstrated that VSMC 
migration and proliferation are enhanced in AAA tissues compared to that in 
aortic occlusive disease and normal inferior mesenteric artery tissues (Patel 
et al., 1996). The same team also showed that these aortic SMCs produce 
increased levels of matrix metalloproteinases (MMPs) compared to those 
produced in control arterial tissues (Patel et al., 1996); these MMPs 
contribute to the degradation of elastin and various ECM proteins, 
progressively leading to degradation of the aortic wall. In the following year, 
another study revealed that the SMC density in the medial layer is 
significantly decreased in AAA tissues in association with SMC apoptosis, 
reflecting its role in aortic wall degradation (Lopez-Candales et al., 1997). 
VSMCs usually exhibit a contractile, quiescent phenotype, characterised by 
the expression of proteins such as α-smooth muscle actin, smooth muscle 
myosin heavy chain, and smooth muscle-22α; however, when stimulated by 
injury or stress, they undergo a phenotypic switch to a proliferative and 
migratory state (Owens et al., 2004, Ailawadi et al., 2009, Michel et al., 
2018, Petsophonsakul et al., 2019). In 2009, Ailawadi et al. demonstrated 
that this phenotypic switching is an early event in AAA, based on the 
downregulation of SMC marker genes and upregulation of MMPs (Ailawadi 
et al., 2009). One of the histopathological characteristics of AAA is extensive 
degradation of the aortic ECM, which is facilitated by elastolytic enzymes 
that are produced by VSMCs when they exhibit the proliferative phenotype. 
The ECM is a fundamental component of blood vessels that is produced by 
the cells located in vessel walls and contains fibrous proteins such as 
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collagen and elastin, proteoglycans such as versican, and glycoproteins 
such as thrombospondins and fibronectin. There are numerous kinds of 
ECM with varying compositions that each play different roles in facilitating 
different pathophysiological processes. Proteomics-based approaches have 
revealed distinct differences in the ECM composition between AAA and non-
AAA tissues (Didangelos et al., 2011). Some proteins that have been 
identified to exhibit changes in AAA include collagen XII, which is found in 
tissues subject to high tensile forces; versican, a major extracellular 
proteoglycan; periostin and thrombospondins, which contribute to cellular 
adhesion and spreading; ACLP, which is known to be associated with 
collagen and fibrosis; and tenascin, which is correlated with macrophage 
accumulation (Satta et al., 1997, Layne et al., 1998, Theocharis et al., 2001, 
Didangelos et al., 2011). These ECM proteins significantly modulate VSMC 
phenotypic switching, and their reduction reflects the pathological 
remodelling of the ECM and VSMCs in the AAA disease course. Finally, 
calcification—the deposition of calcium phosphate crystals in the medial 
layer of the vessel wall—further contributes to vessel stiffening, and hence, 
VSMCs have been shown to contribute to vascular calcification (Proudfoot et 
al., 2000, Shanahan et al., 2011, Wu et al., 2013). Overall, synthetic VSMCs 
are associated with a loss of contractile proteins, greater production of 
elastolytic enzymes that degrade the ECM, the release of extracellular 
vesicles that promote inflammation and calcification, and presence of 
reactive oxygen species (Kapustin and Shanahan, 2016, Schurgers et al., 
2018). These key biological processes thus collectively contribute to 
inducing vessel dilatation and aneurysm progression.  
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Figure 1.2 Flow diagram of the mechanisms contributing to AAA 
formation and progression.   
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Late-stage AAA is understood to involve an amalgamation of VSMC 
apoptosis, upregulated inflammatory cell infiltration, thinning of the aortic 
wall due to an imbalance between the concentrations of collagen and 
elastin, and calcification; these components collectively exacerbate focal 
aortic wall weakening, eventually resulting in rupture (MacSweeney et al., 
1994, Wills et al., 1996, Lopez-Candales et al., 1997, Proudfoot et al., 2000, 
Rowe et al., 2000, Clement et al., 2019, Quintana and Taylor, 2019). The 
prediction of rupture risk is an important area of research, and in this 
context, mechanical properties of the aorta in relation to breaking stress and 
stiffness are well studied. Per the Law of Laplace, intraluminal pressure, wall 
thickness, and vessel diameter affect the wall tension necessary to counter a 
given internal fluid pressure, which in turn affects wall stress. Aneurysm 
rupture occurs when the wall stress exceeds wall tension (Vorp, 2007). 
Studies of the biomechanical properties of aortic aneurysms typically involve 
computational modelling and finite element methods to apply an array of 
proposed criteria that may help predict rupture risk: expansion rate, wall 
tension, wall stiffness, peak wall stress, intraluminal thrombus thickness, and 
surface area (Hall et al., 2000, Hatakeyama et al., 2001, Metaxa et al., 2017, 
van Disseldorp et al., 2019). For example, Conlisk et al. demonstrated that 
sites of greater curvature exhibit increased stress, which then corresponds 
with a greater susceptibility of rupture (Conlisk et al., 2017). Importantly, 
some AAA that are smaller in diameter than the surgical intervention 
threshold exhibit high peak wall stress (van Disseldorp et al., 2019). Recent 
data have suggested that biomechanical assessment may be superior to 
using only the aortic diameter to evaluate rupture risk (Polzer et al., 2020). 
Basing clinical assessments on biochemical parameters in this way may be 
a promising adjunctive tool for precise diagnosis and disease course 
prediction, although their application in the clinic is likely to be hampered by 
the logistical difficulties of obtaining these measurements at repeated time 
points to suffice precise risk prediction as an aneurysm grows and remodels. 
In this case, more subtle stratification biomarkers based on underlying 
molecular mechanisms that come into play before physical appearance of 
the disease may be more feasible to implement in the clinic to predict 
whether patients have a high or low risk of rapidly progressive disease.  
1.3.6 Clinical imaging of AAA 
Current clinical interventions for AAA focus on physically excluding the 
aneurysm, which themselves are associated with significant risks. Therapies 
that instead inhibit the progressive deterioration and molecular dysfunction 
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of the aortic wall would decrease the necessity for surgery. Medical imaging 
plays a key role in better understanding the adverse molecular mechanisms 
underlying early AAA formation. Currently, USS is used in the clinic to 
screen for AAA and monitor disease progression over time. Whilst it is 
effective in revealing changes in aortic size and shape over time, the 
technique is not without its limitations. The most salient limitation is that USS 
is operator-dependent; therefore, results from USS depend on a 
sonographer’s experience and accuracy. This creates a two-variable 
problem: individual patient factors and sonographer accuracy. Implementing 
quality control is inevitably difficult, having to rely on standardised guidelines 
to reduce inter-patient and inter-operator variability. An increasingly common 
problem in Western societies is patient size. Larger patients are difficult to 
image via USS due to their greater mass and depth of tissue, which 
attenuates the sound waves reflecting from deeper structures in the body, 
such as the aorta, and back to the transducer. Ironically, it is overweight and 
obese patients who tend to carry a greater risk of developing AAA and would 
most benefit from screening and monitoring. Trapped air and gas can further 
obstruct the findings of USS; therefore, imaging of regions that are close to 
the air-filled bowel is not always ideal (Kornezos et al., 2010, Dobrucki and 
Sinusas, 2020). That being said, with a sensitivity of 95% and specificity of 
nearly 100%, USS is predominantly used in the clinic to screen for AAA 
because of its ease of operability, low costs, low post-imaging workload and 
instantaneous results, and widespread availability (Kumar et al., 2017).  
Abdominal CT without contrast enhancement is equivalent to USS in terms 
of detecting AAA and is typically recommended in patients who cannot 
undergo USS. Meanwhile, CT with contrast enhancement can provide 
information on the presence of thrombus or dissection flaps, but may not 
provide as much information about branch vessel involvement and smooth 
three-dimensional (3D) rendering that CT angiography (CTA) may offer 
(Reis et al., 2017). CTA is another commonly used modality in the clinic for 
AAA. It is notably valuable in pre-intervention planning, such as in assessing 
aortic size, the presence of intraluminal thrombus, the involvement of 
visceral arteries, and extension to other parts of the aorta, and is even 
superior to USS in identifying and measuring the size of aneurysms (Kumar 
et al., 2017, Kyriakou et al., 2020). Use of CTA for maximum diameter 
measurements has been shown to be associated with high intra-observer 
reproducibility (Mora et al., 2014). However, CTA confers high radiation 
doses (Kumar et al., 2017).  
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Magnetic resonance imaging (MRI) has the ability to provide accurate 
anatomical information of AAA with excellent soft-tissue contrast and 
reduced exposure to ionising radiation compared to CT. MRI has previously 
been used to confirm the diagnosis of thrombus and assess blood flow in 
aortic diseases in patients with aortic aneurysms and dissection (Honda et 
al., 1999). Four-dimensional flow MRI has further been utilised to analyse 
changes in blood flow patterns in the abdominal aorta (Liu et al., 2018). 
Although long scan durations are a notable challenge with the use of MRI, 
advances in MRI-based approaches have revealed that 3D non-contrast 
black-blood MRI is associated with decreased scan durations with retention 
of image quality (Zhu et al., 2019). In a prospective study, this method was 
shown to reveal intraluminal thrombi in patients with AAA, with the finding 
that active changes in intraluminal thrombi are associated with large aortic 
diameters and rapid AAA growth (Zhu et al., 2019). Furthermore, magnetic 
resonance angiography (MRA) has a similar sensitivity to that of CTA and 
has also been shown to reveal endoleaks that could not be visualised using 
CT angiography (Wicky et al., 2003). MRA is particularly useful in cases 
wherein intravenous contrast is contraindicated, such as in cases of allergic 
responses or renal dysfunction, and is associated with a lack of ionising 
radiation (Kumar et al., 2017). However, the benefits of MRI and MRA are 
hampered by key disadvantages such as higher associated costs, reduced 
availability of scanners, motion artefacts and patient claustrophobia due to 
long scanning durations, and contraindications in patients harbouring 
pacemakers and metal clips. 
Meanwhile, PET imaging has the potential to offer more precise functional 
information at the molecular level for risk stratification purposes as an 
adjunctive tool to USS-based screening and surveillance. As the primary 
focus of this thesis, section 1.5 is dedicated to a discussion of PET imaging 
in the context of AAA. The use of PET with a suitable radiotracer may be 
beneficial when applied at the time of AAA detection to help personalise a 
surveillance regimen or intervention threshold. Furthermore, there is 
currently no pharmacological treatment for AAA, and the indication for 
surgery is based solely on aortic size from USS. Establishing a 
pharmacological treatment that could slow or even reverse AAA progression 
is the ultimate aim of AAA research, but this necessitates a stratification 
imaging biomarker that could (a) help select patients who would benefit from 
such a treatment, (b) predict AAA growth and refine watchful waiting 
regimens, (c) determine patient-specific intervention thresholds, or (d) be 
applied in all of the aforementioned applications. Much of the dated 
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understanding of late-stage AAA is based on aortic tissue acquired during 
surgery; hence, theories derived from these samples may not accurately 
represent the mechanisms of early-stage disease, when a novel 
pharmacological therapy may be administered. Preclinical studies of AAA 
are the first step in achieving a more thorough understanding of early-stage 
AAA pathophysiology. Understanding the molecular workings of AAA in 
preclinical models can then lead to the development of stratification 
biomarkers that could be translated to the clinic. Following on from this, a 
preclinical model of AAA has been used to investigate a candidate 
radiotracer for PET imaging in this thesis. 
1.4 Preclinical imaging of AAA 
In vivo imaging modalities are the central focus of preclinical research and 
confer the advantage of visualising biological processes in live animals non-
invasively. The multifactorial contributors to the underlying AAA pathobiology 
each act as attractive molecular-level imaging targets to further our 
understanding of the early-stage changes that precede anatomical changes 
in aneurysmal aortae.  
1.4.1 Preclinical models of AAA 
For any disease, the use of clinically relevant animal models is essential to 
shed light on mechanisms of disease progression before clinical testing. 
That being said, no single model is a perfect representative of human AAA 
pathology; therefore, it is ideal to test hypotheses in multiple models. 
Rabbits, pigs, mice, and rats have been used previously to investigate AAA 
(Patelis et al., 2017). Mice are invaluable in studies of AAA for numerous 
reasons. They are small in size and thus convenient as model species; they 
can be easily housed and maintained, and they adapt well to changes in 
their surroundings. Mice are also relatively cost-effective, as large batches 
can be purchased from mass-producers that breed rodents specifically for 
research purposes (Daugherty and Cassis, 2004, Poulsen et al., 2016). 
Furthermore, the mouse genome is very similar to the human genome and 
can be easily modified to study genes of interest. Inbreeding of different 
mouse strains is a standard means to achieve gene knockout or knock-in 
models, the physiological and phenotypic implications of which can then be 
explored. For example, in the context of AAA, hyperlipidaemic mice are 
achieved via the knockout of apolipoprotein E or low-density lipoprotein 
receptors, and mice deficient in lysyl oxidase (resulting in a failure to 
crosslink elastin and collagen) and MMP genes have also been utilised to 
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better understand the role of the ECM (Daugherty and Cassis, 2004, van der 
Weyden et al., 2011). Herein, three commonly used murine models of AAA 
are described: angiotensin II (AngII) infusion in apolipoprotein E-knockout 
(ApoE-/-) mice, aortic application of calcium chloride (CaCl2), and aortic 
application of porcine pancreatic elastase (PPE). 
1.4.1.1 AngII infusion model 
The AngII model is the most commonly used AAA model in mice (Poulsen et 
al., 2016). The result of AngII infusion leading to the development of AAA 
was an unexpected finding of a study conducted to assess the effect of 
increased plasma concentrations of AngII on atherogenesis in ApoE-/- mice 
(Daugherty et al., 2000). AngII is a vasoconstrictor that mediates a variety of 
growth processes, including proliferation. The proliferative effects of AngII 
have long been established in adrenocortical cells (Gill et al., 1977), 
mesangial cells (Bakris and Re, 1993), endothelial cells (Wolf et al., 1996), 
hematopoietic stem cells (Kim et al., 2016), and VSMCs (Johnson et al., 
1992, Yaghini et al., 2010), among other cell types. To study AAA, ApoE-/- 
mice are classically used for this model because of their inherent 
atherosclerotic susceptibility. AngII infusion in wildtype C57BL6/J mice will 
also produce aneurysms, but only in about 10% of animals compared to 
80% of animals with an ApoE-/- background. Low-density lipoprotein 
receptor-deficient mice also exhibit an increased incidence of AAA following 
AngII infusion and are an alternative, as is a prolonged period of high-fat diet 
feeding. Therefore, although an underlying ApoE-/- condition is not necessary 
for AAA development, it appears to significantly enhance the incidence with 
which AAA develops in this model (Deng et al., 2003, Manning et al., 2003). 
In this model, AAA occurs spontaneously in the suprarenal abdominal aorta 
following 28 days of continuous AngII infusion at a dose of 500–1000 
ng/kg/min via an osmotic mini-pump that has been subcutaneously 
implanted laterally into the flank through a midline neck incision without 
conferring an effect on the thoracic aorta (Rateri et al., 2011). Along with 
dilatation of the suprarenal aorta, the aneurysms in this model present with 
atherosclerosis, macrophage accumulation in the elastic lamina, leukocyte 
infiltration, and medial hypertrophy. There is also a predominance of AAA 
development in male mice, with roughly double the incidence than that in 
female mice. These features are similar to those observed in human AAA 
disease (Daugherty et al., 2000). This model is also popular because the 
AAA is progressive, i.e. it continues to grow as long as AngII continues to be 
infused (Tedjawirja and de Waard, 2019). The timeline of biological events in 
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this model is well established, initiating with macrophage infiltration into the 
medial layer of the susceptible aortic region, transmedial dissection that 
results in rapid luminal expansion within the first week of AngII infusion, and 
additional inflammatory mechanisms, such as the formation of an intramural 
thrombus, degradation of elastin, and significant vascular remodelling (Cao 
et al., 2010). It is important to acknowledge that this model is regarded by 
many as an aortic dissection and dissecting aneurysm model; this is 
because the aneurysms that form in this model have been found to be 
preceded by an intramural rather than intraluminal thrombus, medial tears at 
specific side branches instead of circumferential medial degradation, and 
aortic dissection, which are not typical features of human AAA (Trachet et 
al., 2017). This was the main model used for the experiments in this thesis 
for its procedural simplicity and characteristic similarities to AAA disease in 
humans. The most salient difficulty encountered in this model is the high 
AAA rupture rate (rates of 30–50% have been reported previously); most 
ruptures occur within the first week of AngII infusion, thus necessitating a 
greater starting number of animals for experiments involving this model (Cao 
et al., 2010, Nguyen et al., 2011, English et al., 2015).  
1.4.1.2 PPE application model 
The PPE perfusion model was first described by Anidjar et al. in 1990 and 
has been widely used as a murine model of AAA since then. This model 
entails in vivo isolation and cannulation of the abdominal aorta to administer 
elastase, followed by careful repair of the surgical incision. This model is 
technically demanding; murine aortic isolation from the adjacent inferior vena 
cava (IVC) and small lumbar branch vessels can prove to be difficult. In 
addition, there may be differences in the extent of vascular injury due to 
differences in perfusion pressure. Moreover, careful closure of the aortotomy 
whilst avoiding stenosis is imperative to restore antegrade blood flow 
(Anidjar et al., 1990).  
More than two decades later, a modified version of this model wherein PPE 
is applied to the peri-adventitial aorta was introduced by Bhamidipati et al. to 
overcome the complexities associated with the PPE perfusion model. Their 
model can be achieved without individual vessel manipulation and generates 
aneurysms that involve greater accumulation of activated macrophages, 
elastic lamina degradation, decreased expression of smooth muscle protein, 
and enhanced matrix metalloproteinase activity, similar to that observed in 
other experimental AAA models (Bhamidipati et al., 2012). This modified 
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model was implemented for the research presented in this thesis for its 
technical simplicity. 
The PPE model rarely if ever demonstrates rupture in comparison to the 
AngII model. Atherosclerosis is not a feature of the PPE model, whilst AAA 
in this model is associated with medial degeneration, leukocyte infiltration, 
and formation in the infra-renal abdominal aorta as the key features 
resembling human AAA. However, the PPE model is a non-progressive 
model of AAA, as the disease stabilises after a period of several days or 
weeks due to healing of the biological process (Senemaud et al., 2017).  
1.4.1.3 CaCl2 application model 
The CaCl2 model is another non-progressive model of AAA that involves 
peri-aortic application of CaCl2 to the infra-renal aorta, which induces AAA. 
In 1988, Gertz et al. first demonstrated that the application of CaCl2 to the 
adventitia of a carotid artery resulted in the formation of an aneurysm. This 
aneurysm was accompanied by a decrease in VSMCs, elastin calcification, 
and inflammatory cell infiltration (Gertz et al., 1988). In 1997, this approach 
was reported to induce AAA in New Zealand rabbits (Freestone et al., 1997). 
Finally, this model was first described in mice by Chiou et al. who reported a 
110% increase in diameter 3 weeks after CaCl2 treatment. This model is 
based on the high affinity of calcium for elastin; disrupting this affinity 
weakens the vascular wall, activates inflammatory processes, and eventually 
leads to aneurysm development. Furthermore, AAA in this model is 
accompanied by the depletion of VSMCs, degradation of elastin, infiltration 
of inflammatory cells, and high circulating levels of inflammatory markers 
(Chiou et al., 2001, Wang et al., 2013). Disruption of elastic tissue by 
calcium depositions has been demonstrated in human atherosclerosis; in 
addition, calcification of the human aorta is observed in older adults, and 
approximately 80% of human AAA exhibit calcification of the aortic wall 
(Jayalath et al., 2005, Maier et al., 2010, Kamenskiy et al., 2018). These 
findings make the CaCl2 model a relevant model of human AAA. However, 
thrombus and rupture, which are observed in human AAA, are not features 
of CaCl2-induced AAA (Wang et al., 2013).  
1.4.2 USS 
As the imaging modality of choice in the clinic, USS has also been used 
extensively in preclinical research to investigate morphological aspects of 
AAA. The feasibility of 3D micro-USS in monitoring aneurysm growth has 
been demonstrated in mice via comparisons with histological images 
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(Goldberg et al., 2007). High-frequency USS, which is better suited to 
visualise superficial body structures and can produce images of high axial 
resolution compared to low-frequency USS, has also been used extensively 
to detect AAA in mice based on measurements of luminal diameter and 
aortic wall thickness (Martin-McNulty et al., 2005, Barisione et al., 2006, 
Azuma et al., 2011). USS is a feasible modality to assess changes in aortic 
strain (Favreau et al., 2012). Moreover, preclinical USS combined with a 
semi-automatic image processing algorithm has been shown to reveal 
changes in arterial distension, which may prove to be informative as an early 
marker of arterial disease in animal models (Janus et al., 2018). USS can be 
challenging in mice with AAA; aortic rupture has been reported to occur 
during USS, implying that pressure from the probe on the abdominal region 
may be sufficient to induce rupture. 
1.4.3 MRI 
MRI uses strong magnetic fields and radiofrequency pulses to produce high-
resolution images without the need for ionising radiation (Brangsch et al., 
2017). MRI can be implemented with various probes that have different 
targets to elucidate AAA mechanisms and potentially act as distinct 
biomarkers supplemental to aortic diameter. Botnar et al. demonstrated the 
feasibility of using a fibrin-specific MRI probe to investigate fibrin content in 
the AngII AAA mouse model (Botnar et al., 2018). Bazeli et al. used 
contrast-enhanced MRI to detect MMPs in the rat elastase model of AAA, 
demonstrating a correlation between MMP activity and inflammation (Bazeli 
et al., 2010). Furthermore, a newly developed smart MRI nanoprobe has 
recently been demonstrated to be useful in detecting MMP activity in the 
AngII AAA mouse model and potentially correlating with severe progression 
or rupture (Yao et al., 2020). Brangsch et al. demonstrated the use of dual-
probe MRI to evaluate ECM degradation and inflammatory activity in the 
AngII AAA murine model, which could then be associated with AAA rupture 
risk (Brangsch et al., 2019). Dysfunctional ECM remodelling has further 
been investigated using a gadolinium-based contrast agent specific to 
tropoelastin, the soluble precursor to elastin, which was then shown to 
correlate with accumulated tropoelastin in human aneurysmal tissue (Lavin 
et al., 2019). MRI has also been used to quantitatively analyse aortic motion 
and curvature, as well as changes in aortic size following an intervention in 
mice with AAA (Turner et al., 2008, Goergen et al., 2011). MRI has also 
successfully been used perioperatively to guide EVAR in a swine model of 
AAA, raising the possibility of its role in the clinic during EVAR in patients 
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who are not suitable to undergo CTA (Raman et al., 2005). Despite its 
limitations associated with long scan durations and high costs, as a sensitive 
technique that confers excellent soft tissue contrast, MRI for AAA is a 
growing field of research. 
1.4.4 CT 
CT uses X-rays to generate three-dimensional images with or without 
contrast agents for target enhancement. Although CT is typically used as a 
supplement to functional imaging techniques, such as PET and SPECT, 
Wang et al. recently demonstrated that utilising gold nanoparticles as 
contrast agents with micro-CT can help predict elastin damage and rupture 
pressure in the AngII AAA mouse model (Wang et al., 2019). A CT-based 
method that targets phagocytosis to image vessel wall inflammation in the 
same model has also been developed (Toczek et al., 2018).  
1.4.5 Single-photon emission computed tomography 
Single-photon emission computed tomography (SPECT) is a modality that 
involves the detection of emitted gamma photons following the injection of 
radiotracers such as 99mTc, 123I, and 111In. Golestani et al. used SPECT with 
RP805, a [99mTc]-labelled tracer that targets matrix metalloproteinases 
(MMPs), to demonstrate that MMP-targeted SPECT may indicate aortic wall 
inflammation and help predict expansion or rupture in AAA (Golestani et al., 
2015). Toczek et al. also used SPECT, but with a novel pan-MMP tracer 
called RYM1, to successfully demonstrate specific detection of MMP and 
inflammatory activity in AAA (Toczek et al., 2017). As a lower-cost option 
compared to PET, the application of SPECT to investigate AAA is promising, 
particularly as its spatial resolution is superior to that of preclinical PET 
(approximately 0.25 mm vs. 1 mm). The main obstacle lies in the translation 
of SPECT to the clinic, as clinical SPECT scanners have poorer resolutions 
than those of clinical PET scanners. SPECT is closely related to PET, which 
is the central focus of this thesis, thus warranting a more focussed separate 
discussion in the following section. 
1.5 PET 
Molecular imaging utilises biologically specific tracer molecules to target, 
characterise, and quantify cellular and subcellular pathways and processes 
(Fernandez-Friera et al., 2014, Golestani et al., 2016). PET is a molecular 
imaging modality that relies on radioactive tracers to generate three-
dimensional images of functional processes within the body. The working 
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principle of PET involves the simultaneous detection of two gamma-ray 
photons emitted in opposite directions after the annihilation between an 
electron and tracer-emitted positron. Reconstructed images based on the 
localisation of pairs of photons then reveal the distribution of injected 
radioactive tracer throughout the body, effectively producing a three-
dimensional functional map that is biologically specific to the injected tracer. 
These reconstructions may incorporate corrections that have been made for 
attenuation, scatter, dead time, and random photon coincidences, which 
further improve the spatial resolution of images (Ramaswamy et al., 2013, 
Tarkin et al., 2016). 
1.5.1 Data analysis 
Quantitative measurements are a defining feature of nuclear medicine 
techniques such as PET, allowing for the ability to precisely characterise 
physiological parameters of interest to inform the diagnosis, staging, and 
monitoring of various diseases. To provide anatomical context to supplement 
quantitative data, stand-alone PET imaging systems are often coupled with 
CT or MRI to compensate for the limited spatial resolution of PET; the 
integration of a function-dominant modality (PET) with readily available 
structure-dominant modalities (CT, MRI) improves the quantitative analysis 
of biological functions (Golestani et al., 2016).  
PET/CT can counter some of the caveats associated with USS and, more 
importantly, supplement the information acquired from USS. Unlike USS, 
PET is operator-independent, as it relies on an automated scanner and a 
radiotracer, the activity distribution of which is independent of patient factors 
such as obesity; this feature makes PET an objective technique. Large 
patients, as long as they fit within the scanner, can undergo PET scans with 
minimal effects of tissue depth on the resultant PET signal. One concern 
involving PET is the possible inter-analytical variability depending on how 
the region of interest (ROI) is defined. There is ongoing research to 
standardise ROI definitions and analytical methods, and a significant 
advantage of PET is that data can be reviewed and corrected post-
acquisition using analytic methods to correct for temporal and spatial 
resolution, something that USS that does not yet offer. Meanwhile, 
standardising the human error that contributes to operator-dependent 
variability in USS is difficult (Veronesi et al., 2015, Comelli et al., 2018). 
PET image analysis often relies on the standardised uptake value (SUV) 
metric, a widely used radioactivity quantifier that takes the injected activity 
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and body weight of the subject into account. SUVs are calculated using the 
following equation (Equation 1.2): 
𝑆𝑈𝑉 =
𝑅𝑎𝑑𝑖𝑜𝑎𝑐𝑡𝑖𝑣𝑖𝑡𝑦 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 𝑖𝑛 𝑎 𝑟𝑒𝑔𝑖𝑜𝑛 𝑜𝑓 𝑖𝑛𝑡𝑒𝑟𝑒𝑠𝑡 (
𝑘𝐵𝑞
𝑚𝐿 )
𝐼𝑛𝑗𝑒𝑐𝑡𝑒𝑑 𝑎𝑐𝑡𝑖𝑣𝑖𝑡𝑦 (𝑘𝐵𝑞)
𝐵𝑜𝑑𝑦 𝑤𝑒𝑖𝑔ℎ𝑡 (𝑔)
 
Equation 1.2 Standardised uptake value 
The resultant value is unitless (g/mL, where g and mL are equivalent), 
representing radiotracer accumulation in a given ROI. SUV thresholds are 
commonly used in clinical practice as a basis for disease classification and 
criterion for diagnoses, particularly in the cancer field; for example, regions 
of radioactive glucose uptake (further described in section 1.5.2) may 
indicate where a tumour is located and how aggressive and metabolically 
active the cancer might be (Kinahan and Fletcher, 2010, Nakajima et al., 
2012, Hofman and Hicks, 2016). Use of the SUV to aid diagnosis is 
controversial based on the notions that (a) relative image appearance may 
suffice for diagnostic purposes and (b) calculated SUVs exhibit high 
variability due to non-standardised methods of image acquisition, 
reconstruction, and analysis. However, the SUV may be better used as a 
trend marker, especially in conservative surveillance, wherein clinicians 
might evaluate trends in SUV change to decide how to advance with 
treatment options in AAA; it may be useful to determine whether a ‘watch-
and-wait’ strategy should be adopted to avoid performing invasive 
procedures that may not be necessary for AAA management (Gambhir, 
2002, Boellaard et al., 2004, Kinahan and Fletcher, 2010).  
Despite the widespread use of the SUV, its quantification may be largely 
affected by a number of physiological (e.g. body weight and composition, 
mode of radiotracer administration, time between radiotracer administration) 
and physical (e.g. scanner calibration, reconstruction parameters, ROI 
definition) factors. A variation of 10–25% in repeated SUV measurements 
can be expected in the same patients due to instrument-related and 
analytical factors (Fahey et al., 2010, Kinahan and Fletcher, 2010). The most 
common methods of calculating the SUV are based on the average or 
maximum SUV of all voxels within a predefined ROI (SUVmean and SUVmax, 
respectively). Although the SUVmean shows less sensitivity to image noise, it 
is subject to intra- and inter-observer variability, as it is highly dependent on 
the voxels that are included in the final calculation. Meanwhile, the SUVmax is 
largely independent of the ROI definition, as it reflects the single ‘hottest’ 
voxel value; however, it may be adversely affected by image noise (Massaro 
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et al., 2009, Vanderhoek et al., 2013). In an effort to reduce the variability in 
SUVs, other methods of calculating the SUV have been explored, wherein 
the average SUV in a group of voxels surrounding the ‘hottest’ voxel value is 
determined. This is achieved by applying specific threshold values to 
calculate the SUVmean for voxels within predefined ROIs that are equal to or 
greater than the ‘hottest’ voxels. This approach may maintain the 
reproducibility of the SUVmax with improved statistics to reduce noise 
(Nakamoto et al., 2002, Krak et al., 2005, Velasquez et al., 2009). Averaging 
the 10 ‘hottest’ voxels has been shown to reduce the variability in the 
SUVmax by a factor of 2.7 (Burger et al., 2012). In similar studies, different 
threshold values have been investigated, ranging from 40% to 90% of the 
highest values, which evidently raises the need for a standardised 
percentage threshold that can be applied consistently to provide uniform 
SUV results (Boellaard, 2009, Wahl et al., 2009).  
In addition to the quantitative threshold, the morphology of the ROI also 
contributes to SUV quantification. Manually drawing the ROI to precisely 
delineate the area of tracer uptake is the most intuitive and simple 
segmentation method. However, this method is time-consuming and highly 
subjective, leading to variability in the results (Velasquez et al., 2009, 
Vorwerk et al., 2009). Alternatively, implementing fixed-size ROIs permits 
semi-automatic delineation of areas of tracer uptake, hence requiring less 
time than that required for manual delineation (Nakamoto et al., 2002, Benz 
et al., 2008, Vanderhoek et al., 2013). Different sizes and shapes of fixed-
size ROIs have been explored, including square, cylindrical, and spherical 
regions with side lengths ranging from 7 to 15 mm (Nahmias and Wahl, 
2008, Weber et al., 2015). Moreover, advanced automatic image 
segmentation methods that utilise properties of image reconstruction 
algorithms, such as edge detection, region growing, and fuzzy locally 
adaptive Bayesian methods, are under continuous development (Day et al., 
2009, Hatt et al., 2010); this domain has evolved to what is now called 
‘radiomics’. Studies of the effects of different thresholds on SUV 
quantification have largely used data from the oncology field; however, the 
implications of the results are also useful for cardiovascular and other 
medical fields.  
Another metric that is commonly implemented in PET image analysis is the 
target-to-background ratio (TBR). The TBR takes the SUV a step further, in 
dividing the target lesion’s SUV with the venous blood pool SUV, as follows 
(Chen and Dilsizian, 2015) (Equation 1.3): 
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𝑇𝐵𝑅 =
𝑆𝑈𝑉𝑡𝑎𝑟𝑔𝑒𝑡
𝑆𝑈𝑉𝑏𝑎𝑐𝑘𝑔𝑟𝑜𝑢𝑛𝑑
 
Equation 1.3 Target-to-background ratio 
Doing so corrects the SUV for blood uptake of the tracer, enabling 
researchers and clinicians to differentiate between radiotracer uptake in a 
target lesion versus radioactivity due to radiotracer that has not been taken 
up into cells and has instead remained in the blood supply circulating around 
the target lesion. Nonetheless, similar to the use of the SUV, the use of the 
TBR is also controversial. The TBR depends on how the blood pool activity 
is measured, reflecting the denominator in the ratio. This measure could be 
acquired from the superior vena cava, IVC, right atrium, or jugular vein, a 
source that varies across different studies. Furthermore, the blood pool 
activity may vary because of biological (e.g. differential renal clearance) or 
analytical (e.g. differential ROI definitions or low spatial resolution) reasons 
(Chen and Dilsizian, 2015). Regarding this, Huet et al. implemented a 
mathematical model that summed vascular wall activity and blood activity 
with adjustments based on weighting factors considering activity spill-out. 
They suggested that differences in the TBR result from notable differences 
in vascular wall activity and in estimated blood pool activity, rendering the 
TBR less reproducible than the SUV (Huet et al., 2015). Improvements in 
spatial resolution and application of partial volume correction may enhance 
the precision and accuracy of methods of PET analysis in the future 
(Tsoumpas et al., 2016). 
1.5.2 PET radiotracers 
The most common radioactive tracer used in PET imaging is [18F]FDG, an 
analogue of glucose. Uptake of [18F]FDG occurs in cells that metabolise 
glucose, after which it is phosphorylated by hexokinase into [18F]FDG-6-
phosphate. At this stage, it is then metabolically trapped, as it does not 
harbour the 2’ hydroxyl group that is essential to proceed with glycolytic 
reactions (Figure 1.3). Therefore, the intracellular distribution of [18F]FDG is 
associated with the degree of metabolic activity and inflammation in regions 
of uptake (Tarkin et al., 2016). [18F]FDG uptake on PET has been 
demonstrated to be correlated with macrophage density in plaques, 
cardiovascular risk factors, the Framingham Risk Score, and various 
inflammatory and glycolysis-related biomarkers, such as glucose transporter 
(GLUT)-1, GLUT-3, and total lesion glycolysis (Zhao et al., 2002, Tarkin et 
al., 2014, Suzuki et al., 2018). A downside to the advantage of [18F]FDG 
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having the capacity to highlight all regions of active glucose metabolism is 
that, as a result, it is difficult to differentiate disease-specific activity. 
Moreover, the uptake of [18F]FDG can be influenced by conditions of disease 
microenvironments, such as hypoxia or increased myocardial muscle 
activity, or the efficiency with which the microcirculation distributes the 
radiotracer (Wykrzykowska et al., 2009, Folco et al., 2011, Taqueti et al., 
2014). To help overcome these and similar limitations, novel radioactive 
tracers are continually under development to elucidate different 
pathobiological mechanisms in different diseases.  
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Figure 1.3 Schematic of the metabolic pathway of glucose and its 
analogue [18F]FDG. [18F]FDG, [18F]fluorodeoxyglucose; [18F]-FDG-6P, 
[18F]fluorodeoxyglucose-6-phosphate; GLUT1, glucose transporter-1; 
HK, hexokinase; G6Pase, glucose-6-phosphatase; Glucose-6P, 
glucose-6-phosphate; TCA, tricarboxylic acid.   
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Primary research studies of AAA involving PET imaging that have been 
conducted in the last decade are presented in Table 1.2. There has been an 
extensive focus on markers of inflammatory activity, evidenced by the 
overwhelming predominance of [18F]FDG PET studies. Both preclinical and 
clinical studies of gold-standard [18F]FDG PET to assess glucose 
metabolism and inflammation in AAA have yielded varying results, with both 
increased and variable [18F]FDG uptake being demonstrated (Sakalihasan et 
al., 2002, Kotze et al., 2011, English et al., 2015, Huang et al., 2016, Nie et 
al., 2018, English et al., 2020). Some studies have shown that [18F]FDG PET 
may be useful to predict AAA expansion and/or progression (Reeps et al., 
2008, Courtois et al., 2013, Nchimi et al., 2014), whilst other studies have 
contradicted this (Kotze et al., 2011, Barwick et al., 2014). For example, 
Reeps et al. showed that increased aortic uptake of [18F]FDG in patients was 
associated with a higher density of inflammatory markers, which may 
contribute to aortic expansion, whilst patients showing [18F]FDG uptake in 
AAA revealed no correlation with aortic expansion 12 months later in a study 
by Kotze et al (Reeps et al., 2008, Kotze et al., 2011). Moreover, Nchimi et 
al. demonstrated that [18F]FDG uptake correlated positively with wall stress 
and strength in AAA, whereas Barwick et al. found no significant difference 
in aortic uptake of [18F]FDG between patients with infra-renal AAA and 
patients without AAA (Barwick et al., 2014, Nchimi et al., 2014). Based on a 
study involving [18F]FDG PET and contrast-enhanced MRI, Kuzniar et al. 
further demonstrated that the hotspots of [18F]FDG uptake and late 
gadolinium enhancement rarely coincide in AAA, although both are 
associated with aneurysm growth, raising questions about the distribution of 
cellular activity in AAA (Kuzniar et al., 2019). Collectively, these findings lend 
to a complicated story of glucose metabolism in AAA. 
Other PET radiotracers are also promising in the context of AAA. The 
Sodium Fluoride Imaging of AAA (SoFIA3) trial has shown that uptake of 
[18F]-labelled sodium fluoride (NaF), which reflects regions of 
microcalcification, in patients with asymptomatic AAA predicts AAA 
progression and rupture, providing proof-of-concept data for the feasibility of 
a non-[18F]FDG PET radiotracer for AAA stratification (Forsythe et al., 2018). 
A key point coming out of this study is that aneurysm size is not necessarily 
a predictor of rupture; AAA growth can be non-linear and influenced by 
biomechanical processes that may not exhibit a detectable pattern. The 
SoFIA3 trial demonstrated that [18F]NaF uptake is a positive predictor of 
aneurysm growth and clinical outcomes, which are independent but 
supplementary to classic clinical parameters such as aneurysm diameter 
35 
(Forsythe et al., 2018). That being said, the findings of this trial must be 
considered in light of the confounding issue of spill-in contamination from the 
nearby bone into the aneurysm; thus, background correction techniques can 
provide more robust quantitative assessments of AAA (Akerele et al., 2019). 
Alternative tracers that may prove to be useful include markers of other 
characteristics of AAA development, such as angiogenesis (Shi et al., 2015) 
and integrins (Kitagawa et al., 2013, Tegler et al., 2014). 
[18F]fluoromethylcholine, which is commonly implemented for staging 
prostate cancer, may also be useful to incidentally detect AAA in patients 
with prostate cancer (Ferda et al., 2019). In this way, PET will undoubtedly 
remain an attractive modality to advance our understanding of AAA 
pathophysiology, whilst novel molecular tracer agents are introduced and 
hybrid multimodality systems are improved. As PET is readily accessible and 
already being used in the clinic, continued research using PET has practical 
applications that are feasible for clinical translation. 
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Table 1.2 Studies using PET imaging to investigate AAA published in the most recent decade. The following Boolean 
operators were used as search terminology: (AAA OR abdominal aortic aneurysm*) AND (PET OR positron emission 
tomography). Only original research articles were included (i.e. reviews, case reports, conference proceedings, etc. were 
excluded). 
Reference Radiotracer Target (Species) Key Conclusions 
(Barwick et 
al., 2014) 
[18F]FDG Glucose metabolism (humans) 
Metabolic activity levels may not correlate with aortic size and 
may not differ between aneurysms vs. controls. 
(Courtois et 
al., 2013) 
[18F]FDG 
Correlation between inflammation 
and histological analysis (humans) 
[18F]FDG uptake in the aneurysmal wall may be associated 
with an active inflammatory process involving proliferating 
leukocytes and increased circulating C-reactive protein. 
(Courtois et 
al., 2018) 
[18F]FDG Circulating miRNAs (humans) 
Specific miRNAs are significantly correlated with [18F]FDG 
uptake in the aneurysmal wall and may be directly involved in 
AAA instability. 
(Courtois et 
al., 2019) 
[18F]FDG 
Prediction of complications after 
EVAR (humans) 
Aortic [18F]FDG uptake may be a predictor of post-EVAR 
complications. 
(English et 
al., 2014) 
[18F]FDG and 
[11C]PBR28 
Aortic wall inflammation (rats) 
AAA wall inflammation can be detected using [18F]FDG and 
[11C]PBR28. 
(English et 
al., 2015) 
[18F]FDG Rupture prediction (rats) 
Increased pre-rupture glucose uptake may be associated with 
increased inflammation in the ruptured AAA wall. 
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(English et 
al., 2020) 
[64Cu]DOTA-
ECL1i 
Expression of chemokine receptor 
2 (rats) 
Chemokine receptor 2 may predict AAA rupture. 
(Ferda et 
al., 2019) 
[18F]FCH 
Incidental AAA detection in 
patients with prostate cancer 
(humans) 
[18F]FCH PET/CT may be an effective approach for secondary 
prevention and stratification of AAA in patients with prostate 
cancer. 
(Forsythe et 
al., 2018) 
[18F]NaF 
AAA growth and clinical outcomes 
(humans) 
[18F]NaF uptake may help identify advanced AAA and may be 
correlated with aneurysm growth and clinical AAA events that 
differ from established risk factors. 
(Huang et 
al., 2016) 
[18F]FDG Structural stress (humans) 
Increased [18F]FDG is associated with high mechanical stress 
of thick intraluminal thrombus in AAA. 
(Kitagawa 
et al., 2013) 
[18F]FPPRGD2 αvβ3 expression (mice) 
[18F]FPPRGD2 uptake in AAA may correlate with vascular 
inflammation and neoangiogenesis. 
(Kotze et 
al., 2009) 
[18F]FDG Metabolic activity (humans) 
There may be increased metabolic activity mediated by GLUTs 
in the AAA wall. 
(Kotze et 
al., 2011) 
[18F]FDG 
Future aneurysm expansion 
(humans)  
AAA with lower metabolic activity may be more likely to 
expand. 
(Kotze et 
al., 2014) 
[18F]FDG 
Correlation between CT texture 
analysis data and metabolism 
(humans) 
CT textural data may reflect AAA metabolism measured by 
[18F]FDG PET. 
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(Kuzniar et 
al., 2019) 
[18F]FDG Inflammation (humans) 
[18F]FDG PET/MRI may be used to assess inflammation in 
asymptomatic AAA, although the hotspots of [18F]FDG uptake 
and late gadolinium enhancement are not always aligned. 
(Lee et al., 
2018) 
[18F]FDG 
Decision to perform intervention 
(humans) 
[18F]FDG uptake may be related to the clinical conditions of 
patients with AAA who require intervention. 
(Maier et 
al., 2012) 
[18F]FDG 
Correlation between metabolic 
activity and non-linear finite 
element analysis (humans) 
Greater [18F]FDG activity may be associated with increased 
mechanical stress in the AAA wall. 
(Marini et 
al., 2012) 
[18F]FDG 
Correlation between [18F]FDG 
uptake and asymptomatic non-
inflammatory AAA (humans) 
Low [18F]FDG uptake in asymptomatic AAA reflects the loss of 
tissue structure and reduced cell density. 
(McBride et 
al., 2016) 
[18F]FDG Vascular inflammation (humans) 
[18F]FDG PET/CT may indicate macrophage glycolytic activity 
in AAA. 
(Menezes 
et al., 2009) 
[18F]FDG 
Ideal imaging time after [18F]FDG 
injection (humans) 
There may be no advantage in terms of image analysis in 
imaging 3 h vs. 1 h after [18F]FDG injection. 
(Molacek et 
al., 2019) 
[18F]FDG AAA progression (humans) 
[18F]FDG PET/CT or PET/MRI does not correlate with disease 
symptoms, AAA progression, or dissection. 
(Morbelli et 
al., 2014) 
[18F]FDG 
Relationship between inflammation 
and risk factors (humans) 
Vascular inflammation plays a role at all stages of AAA, which 
may involve the local result of systemic inflammation.  
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(Morel et 
al., 2015) 
[18F]FDG Metabolic changes (humans) 
Metabolic changes in AAA may follow a cyclic pattern, similar 
to that observed with changes in maximal aortic diameter. 
(Murakami 
et al., 2014) 
[18F]FDG Infection (humans) [18F]FDG PET is useful to diagnose infected AAA. 
(Nahrendorf 
et al., 2011) 
[18F]CLIO Macrophages (mice) 
[18F]CLIO may be used to quantify macrophage content in 
AAA. 
(Nchimi et 
al., 2014) 
[18F]FDG 
Biomechanical properties 
(humans) 
Increased [18F]FDG uptake is correlated with AAA location, wall 
stress, and patient risk factors. 
(Nchimi et 
al., 2016) 
[18F]FDG 
Intraluminal thrombus occurrence 
in AAA (rats) 
Increased [18F]FDG uptake and growth may be associated with 
intraluminal thrombus occurrence in AAA.  
(Nie et al., 
2018) 
[18F]FDG AAA progression (rabbits) Inflammation plays a key role early in AAA development. 
(Palombo 
et al., 2012) 
[18F]FDG 
Asymptomatic aneurysmal uptake 
(humans) 
[18F]FDG uptake may be rare in patients with AAA of diameter 
approaching the surgical threshold. 
(Reeps et 
al., 2013) 
[18F]FDG 
Correlation between glucose 
metabolism and partial volume 
correction (humans) 
Partial volume correction may be necessary to quantitatively 
stratify patients for AAA repair. 
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(Sarda-
Mantel et 
al., 2012) 
[18F]FDG, 
[18F]FCH, 
[18F]DPA714 
Correlation between aortic wall 
inflammation and histo-
pathological analysis (rats) 
[18F]FDG may have higher sensitivity than that of [18F]FCH and 
[18F]DPA714 in detecting activated leukocytes in the 
aneurysmal wall. 
(Shi et al., 
2015) 
[64Cu]NOTA-
TRC105-Fab 
Angiogenesis (mice) 
[64Cu]NOTA-TRC105-Fab uptake indicates regions of 
increased angiogenesis in AAA, based on CD105 expression.  
(Tegler et 
al., 2012) 
[18F]FDG Inflammation (humans) 
[18F]FDG PET cannot be used to detect chronic inflammation in 
asymptomatic aneurysms. 
(Tegler et 
al., 2013) 
[11C]PK11195 
and [11C]-d-
deprenyl 
Inflammation (humans) 
Inflammation in AAA cannot be detected using [11C]PK11195 
and [11C]-d-deprenyl. 
(Tegler et 
al., 2014) 
[18F]-
fluciclatide 
αvβ3 expression (humans) 
αvβ3 integrin expression in AAA may be visualised using 
[18F]fluciclatide 
(Truijers et 
al., 2009) 
[18F]FDG Aneurysm wall pathology (humans) 
[18F]FDG PET/CT may be useful in detecting concomitant 
malignancies in patients with AAA. 
(Tsuruda et 
al., 2016) 
[18F]FDG Aortic wall inflammation (humans) 
Active aortic wall inflammation may contribute to AAA 
progression and rupture.  
(Xu et al., 
2010) 
[18F]FDG 
Wall stress and metabolic activity 
(humans) 
High AAA wall stress and accelerated metabolism may be 
associated. 
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AAA, abdominal aortic aneurysm; CD105, cluster of differentiation-105; CT, computed tomography; EVAR, endovascular aneurysm 
repair; [18F]CLIO, [18F]dextran-coated iron oxide; [18F]FCH, [18F]fluoromethylcholine; [18F]DPA714, [18F]N,N-diethyl-2-[4-(2-
fluoroethoxy)phenyl]-5,7-dimethylpyrazolo[1,5-a]pyrimidine-3-acetamide; [18F]FDG, [18F]fluorodeoxyglucose; [18F]NaF, [18]sodium 
fluoride; GLUT, glucose transporter; miRNA, microRNA; MRI, magnetic resonance imaging; PET, positron emission tomography 
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1.5.3  [18F]FLT and thymidine 
A key idea underlying this thesis, as described in section 1.3.5, is that AAA 
formation involves cell proliferation, which may be a feasible target for 
[18F]FLT PET. [18F]FLT is an example of a radioactive PET tracer that is 
useful to elucidate a non-glucose activity mechanism: cell proliferation. 
[18F]FLT has a similar structure to that of thymidine, with the exception of the 
fluorine atom that replaces the hydroxyl group at the 3’ position; this precise 
positioning prevents [18F]FLT from proceeding along the complete 
mechanistic pathway of thymidine. Once [18F]FLT is actively transported 
from the blood into cells, it acts as a substrate for thymidine kinase (TK)-1, a 
cytosolic enzyme with peak expression during the synthesis phase of the cell 
cycle and very low expression in resting cells (He et al., 2004). At this stage, 
it is phosphorylated and metabolically trapped within the cell, such that it is 
restricted from incorporating into DNA (Figure 1.4). 
Few researchers have attempted kinetic analysis for [18F]FLT quantification 
in PET imaging of non-neural regions. However, a mathematical model 
similar to that for [18F]FDG has been established, which consists of (i) an 
extracellular blood pool compartment shared by [18F]FLT and thymidine; (ii) 
an exchangeable tissue compartment, from which [18F]FLT and thymidine 
exchange freely between the blood pool or continue to be metabolised 
intracellularly; and (iii) a compartment of phosphorylated (and thus trapped) 
[18F]FLT nucleotides. Four rate constants are used to define the kinetic 
transfer rates between these two compartments and blood. The transfer 
from blood into tissue is represented by K1, with k2 representing the return of 
non-phosphorylated [18F]FLT from tissue. The phosphorylation of [18F]FLT is 
conveyed through k3, which is the rate-limiting step of [18F]FLT retention in 
tissue (Shields et al., 2002, Muzi et al., 2006). These phosphorylated 
products then show negligible dephosphorylation back to the extracellular 
compartment, represented by k4, as [18F]FLT is not a substrate for thymidine 
phosphorylase (Grierson et al., 2004).  
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Figure 1.4 Schematic of the metabolic pathway of thymidine and its 
analogue [18F]FLT. TK-1, thymidine kinase-1; dNT, 
deoxyribonucleotidase; DNA, deoxyribonucleic acid; [18F]FLT, 
[18F]fluorothymidine; [18F]-FLT-MP, [18F]fluorothymidine-
monophosphate; Thymidine-MP, thymidine-monophosphate.    
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Based on the notion that TK-1 activity is directly associated with the 
concentration of [18F]FLT in cells, [18F]FLT signal and uptake are reflective of 
proliferative activity. Phosphorylated [18F]FLT is unable to escape from cells 
and has been demonstrated to act as a substrate for TK-1 and not for 
mitochondrial TK-2, the latter being cell cycle-independent, making [18F]FLT 
a tracer that exhibits high specificity for its biological target (i.e. proliferative 
cells) (Hannigan et al., 1993, Toyohara et al., 2002). Furthermore, the 
compartmental model of [18F]FLT indicates that the metabolic flux 
parameter, KFLT, which is a product of the rate constants, is strongly 
correlated with the Ki67 proliferative index as well as TK-1 expression (Muzi 
et al., 2005, Brockenbrough et al., 2011). 
The utility of [18F]FLT in cancer imaging has been extensively demonstrated 
because its biological target is one of the key hallmarks of cancer (Shields et 
al., 1998, Salskov et al., 2007, Yue et al., 2010, Hanahan and Weinberg, 
2011, Viertl et al., 2011). Furthermore, Ye et al. demonstrated that [18F]FLT 
PET could be used to visualise proliferating macrophages, hematopoietic 
stem cells, and progenitor cells in preclinical and clinical models of 
atherosclerosis (Ye et al., 2015). Their findings highlight the promise of 
[18F]FLT PET for non-cancer applications; however, its usefulness for other 
cardiovascular applications is unclear.  
1.6 Research hypotheses, aims, and objectives 
The hypothesis to be tested in this thesis is that there is an active period of 
cell proliferation in AAA that can be detected using [18F]FLT PET/CT and 
modulated in response to anti-proliferative drugs. To test this hypothesis, the 
aim of this thesis was to determine the feasibility of [18F]FLT PET/CT to 
visualise and quantify cell proliferation in the AngII AAA murine model. The 
key objectives of this study were to  
(i) investigate if there is significant [18F]FLT uptake in the aneurysms of the 
AngII and PPE AAA mouse models;  
(ii) evaluate the expression of key proteins involved in the thymidine 
proliferative pathway; 
(iii) investigate a variety of image quantification metrics by assessing the 
effects of different ROI definitions; and 
(iii) determine if [18F]FLT PET/CT can be used to assess a therapeutic 
response in the AngII AAA model. 
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Chapter 2 Methods 
This chapter provides an overview of the methods implemented to conduct 
the experiments presented in this thesis. The rationale for each method 
chosen is also described. 
2.1 Animal models 
All animal work was conducted in accordance with the UK Home Office, 
Animals (Scientific Procedures) Act 1986 under Project Licence P606320FB. 
Male JaxTM ApoE-/- mice (B6.129P2-Apoetm1Unc/J; Charles River, UK) 
underwent surgery at 14 weeks of age. Male C57BL6/J mice (Charles River, 
UK) were used at 8 weeks of age for baseline biodistribution studies. Male 
mice were chosen for the overall study as AAA predominantly occurs in male 
patients (Bloomer et al., 2012). All animals were part of the Jackson 
Laboratories Genetic Stability Programme to limit cumulative genetic drift. 
Mice were maintained at 21°C with a 12-hour light / dark cycle and 50–70% 
humidity in GM500 individually ventilated cages (Techniplast, Italy) with a 
maximum of 5 animals per cage and fed a standard RM1 chow pellet diet 
(Special Diet Services) and triple-filtered water via Hydropac pouches ad 
libitum. All mice were provided with a housing dome and two chew sticks as 
environmental enrichment. All mice were checked daily by an animal 
technician.  
The traditional murine AAA models were generated as described below. All 
surgical procedures were performed under isoflurane anaesthesia via 
inhalation (to allow for tight control of anaesthetic depth with rapid recovery) 
in a purpose-built murine operating facility under sterile surgical conditions 
using an OPMI Pico operating microscope (Zeiss) in accordance with the 
guiding principles of the laboratory animal science association 
(www.lasa.co.uk) by Dr Marc Bailey. Mice were maintained at 37°C during 
surgery and recovery using a heated operating table and recovery platform. 
Wounds were closed using continuous Vicryl (Ethicon) sutures, 6-0 for the 
peritoneum and 4-0 for the skin. All animals received suitable buprenorphine 
analgesia via intraperitoneal injection (100 μL of 0.1 mg/mL solution with 
additional 50-μL injections as needed). Mice were identified by ear notching. 
The AngII AAA model was the main model used for the experiments 
presented in this thesis because of (i) the favourable location of the AAA 
distant from the bladder, which would impart partial volume effects, and (ii) 
its surgical ease, as these mice needed to undergo surgery at the University 
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of Hull, where the surgical facilities were limited. For this model, 14-week-old 
male ApoE-/- mice (Jackson Laboratories) received human AngII (Sigma 
A9525) infusions at 750 ng/kg·min via Alzet® 1002 (14 days) or 1004 (28 
days) osmotic mini-pumps that were implanted subcutaneously by posterior 
neck incision under recovery isoflurane anaesthesia, as described previously 
(Bridge et al., 2017). Matched male ApoE-/- mice infused with a saline 
solution were used as controls for this model.  
For the PPE model, 12-week-old male C57BL6/J mice were subjected to 
laparotomy, and the abdominal aorta was exposed by blunt dissection. PPE 
(10 µL, Sigma E1250) was applied to the adventitia of the infra-renal aorta 
for 5 min. For the CaCl2 model, the approach was identical to that of the PPE 
model, but CaCl2 (0.5 M) was applied to the adventitia of the infra-renal aorta 
for 14 min on disassociated cotton bud tips. Sham-operated matched male 
C57BL6/J mice were used as controls for both the PPE and CaCl2 models; 
these animals underwent identical laparotomy and aortic exposure, but 
saline washout only. 
For all mice used for experiments at the University of Hull, the presence of 
AAA was determined based on visual inspection at post-imaging necropsy 
(i.e. the presence or lack of AAA) because of the limited resources available 
at this site; moreover, it was difficult to grade the severity of the AAA without 
access to a microscope. For all mice used for experiments at the University 
of Leeds, the presence of AAA was determined using USS, which also 
provided measurements of size. 
2.2 Histological staining 
For the initial experiment investigating cell proliferation in murine models of 
AAA, AAA was first induced in mice by three methods: AngII infusion to 
ApoE-/- mice or peri-adventitial application of CaCl2 or PPE to the aorta in 
C57BL6/J mice, as described in section 2.1. In each case, AAA tissues were 
compared with equivalent tissues from appropriate and matched sham 
control animals. The aortic tissues were harvested at 28 days post-induction 
of AngII and CaCl2 AAA and at 14 days post-induction of PPE AAA (per the 
standard time points of the models) and used for 3,3′-diaminobenzidine 
staining for proliferative cells using an antibody raised against the cell 
proliferation marker Ki67. The Ki67 index is defined by the proportion of cells 
in a specified ROI with positive immunohistochemical staining and has been 
demonstrated to be particularly useful in cancer research to monitor the 
proliferative rate of tumour cells (Scholzen and Gerdes, 2000). Ki67 protein 
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expression peaks in cells throughout the active G1, S, G2, and M cell cycle 
phases, with drastically reduced expression in resting cells (i.e. G0) (Miller et 
al., 2018). Therefore, Ki67 was chosen for the initial experiments to explore 
the detectability of cell proliferation in murine AAA models.  
To perform Ki67 staining, the mice were first terminally exsanguinated via 
the IVC. Murine aortae were each fixed in situ by perfuse fixation with 10 mL 
of phosphate-buffered saline followed by 5 mL of 4% paraformaldehyde in 
terminally anaesthetised animals via cardiac puncture with an outflow tract 
through the severed pulmonary arteries. Aortae were then fixed at 4°C for 48 
hours before they were embedded in Cellwax (Cellpath Ltd., UK) using the 
Leica EG1150H embedding station. Four-µm thickness sections were cut 
onto Plus Frost slides (Solmedia, UK) using a Leica RM2235 microtome, 
and the slides were dried overnight at 37°C. Proliferating cells were stained 
with rabbit anti-mouse Ki67 antibody (ab15580, Abcam; 1:750 dilution) for 1 
hour and Menapath Polymer HRP secondary antibody (Menarini Diagnostics 
Ltd., Winnersh, UK) for 30 minutes. The specificity of the antibody was first 
confirmed in positive control (spleen) tissue with and without primary 
antibody. Following a final wash, all sections were treated with Menapath 
diaminobenzidine peroxidase for 5 minutes and counterstained with Mayer’s 
Haematoxylin for 2 minutes, dehydrated, cleared in xylene, and mounted in 
dibutyl phthalate xylene. The slides were then imaged using the Aperio® AT2 
(Leica Biosystems, Wetzlar, Germany) digital pathology slide scanner with 
×20 maximal magnification. Images were stored on the secure Leeds 
Institute of Cancer and Pathology digital pathology server and accessed 
remotely using Aperio® Image Scope software (Leica Biosystems). All 
quantitative analyses were performed using ImageJ 1.51k software 
(Schneider et al., 2012). For quantification of the Ki67 staining, the 
proportions of Ki67-positive nuclei were determined in three 50-µm2 ROIs 
and averaged for each animal. Finally, aortae from control models were 
compared against aortae from the three different aneurysm models. 
2.3 In vivo USS 
To evaluate aortic volumes and diameters, in vivo USS was performed in 
two cohorts: (i) the animals used for Ki67 analysis and (ii) those that were 
subsequently used for [18F]FLT gamma counting analysis. USS was 
performed using the Vevo2100 high-resolution (30 µm), high-frequency 
preclinical µUSS system (Visualsonics, FUJIFILM VisualSonics, Inc., 
Toronto, ON, Canada) with an MS-550D transducer at a 40-MHz frequency 
on a heated platform maintaining a core body temperature of 35°C to 37°C, 
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monitored via a rectal probe. Recovery anaesthesia was induced in the mice 
at 5% isoflurane and maintained at 2%. Prior to imaging, the abdomen area 
was shaved and hair removed using depilatory cream. Imaging was 
performed using Aquasonic® clear gel (Parker Labs). Transverse imaging 
was acquired using a motor along an 11.96-mm ROI from the right renal 
artery in the cranial direction with 157 frames at 0.076-mm intervals gated 
for respiration with electrocardiographic triggering 50 ms after the r-wave. 
Images were reconstructed and measured using Vevo Lab v1.7.0 
(VisualSonics, FUJIFILM VisualSonics, Inc., Toronto, ON, Canada) to 
generate three-dimensional lumen volume measurements. For the co-
registration analysis, bony landmarks on CT and USS images were aligned 
and displayed using ImageJ 1.51k (Schneider et al., 2012). 
2.4 In vivo [18F]FLT PET/CT 
[18F]FLT was prepared from [18F]fluoride produced by a radiochemist at the 
University of Hull using an on-site 7.5-MeV ABT Biomarker Generator 
cyclotron and purified using an in-house developed microfluidic 
electrochemical cell for electrode trapping, through which irradiated target 
water (0.5 mL, [18O]H2O) containing ca. 1 GBq of [18F]fluoride was pumped 
at 0.2 mL/min whilst applying a 20 V potential, and the cell was flushed with 
2 mL of MeCN at 1 mL/min with no potential applied. Subsequently, 0.4 mL 
of a solution containing KHCO3 (30 mM) and K222 (37 mM) in MeCN was 
pumped through the cell at 40°C at 0.1 mL/min. Ten mg of fluorothymidine 
precursor 3’-N-Boc-5’-dimethoxytrityl-3’-O-nosyl-thymidine was added to the 
released solution to perform a radio-labeling reaction at 100°C for 10 min. 
After the fluorination, the unreacted [18F]fluoride was trapped on the neutral 
alumina cartridge (light) and reaction mixture treated for 5 min at room 
temperature with an equivalent volume of 2 N HCl solution. The mixture was 
then neutralised with a stoichiometric amount of 8 N NaOH solution and 
purified by semi-preparative high-performance liquid chromatography 
(HPLC) on an ACE 5 C18 10×250 5A column eluted with 35% acetonitrile in 
water (both 0.1% trifluoroacetic acid) (flow rate=4.7 mL/min, Rt=12 min). The 
HPLC fraction containing partially protected product was diluted 2–3-fold 
with water and passed over an HBL Oasis C18 cartridge. Trapped product 
was eluted with 0.5 mL of ethanol and 3 mL of diethyl ether and dried at 
60°C under an inert gas stream. The heat applied for drying generated the 
fully de-protected [18F]FLT (confirmed by analytical HPLC with a cold 
[19F]FLT standard), which was re-dissolved in 10% ethanol/PBS solution, 
filtered through a 0.22-µm filter for sterility, and delivered for animal 
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administration. Tracer preparation started with 1.0–1.3 GBq of cyclotron-
produced [18F]fluoride and yielded 40±8 MBq (n.d.c.) [18F]FLT intravenous-
injectable formulation in 136±15 min (n=5) (RCY (decay-corrected)=8±2%). 
Prior to imaging for the AngII AAA study, mice were induced with 5% 
isoflurane/oxygen (v/v) anaesthesia before maintenance at 2% at 1 L/min. 
Mice were cannulated in the tail vein using a bespoke catheter before being 
placed into an imaging cell where temperature and respiration were 
monitored (Minerve, France). [18F]FLT was injected with the following means 
± standard deviations (SDs) of activity in 200 µL of 0.9% saline solution 
(Aqupharm No1, Animalcare Ltd., York, UK) through the pre-cannulated 
lateral tail vein at the beginning of a 90-minute dynamic imaging sequence: 
7.27 ± 2.89 MBq (0.20 ± 0.08 mCi) (14-day scans; n=12) and 10.08 ± 1.77 
MBq (0.27 ± 0.05 mCi) (28-day scans; n=7). Images were acquired using the 
Super Argus (Sedecal) small-animal PET/CT scanner installed at the 
University of Hull, with animals placed prone and the field-of-view centred on 
the abdominal aorta. Mice were maintained at 1% anaesthesia during 
scanning, with temperature and respiration monitored throughout. Following 
the 90-minute dynamic PET scan, a CT image was acquired for anatomic 
co-registration (40 kV, 140 µA, 360 projections, 8 shots). PET images were 
histogrammed into 15 2-second, 2 15-second, 4 60-second, 1 300-second, 
and 8 600-second frames and reconstructed using the 3D ordered subsets 
expectation maximisation algorithm with 2 iterations and 16 subsets with 
attenuation correction (as standard protocol at the University of Hull), 
yielding voxel dimensions of 0.39 × 0.39 × 0.78 mm3. 
Prior to imaging for the PPE model and imatinib studies, mice were induced 
with 5% isoflurane/oxygen (v/v) anaesthesia before maintenance at 2% at 1 
L/min. [18F]FLT was injected at mean ± SD doses of 9.3±0.7 MBq and 
9.4±0.1 MBq in 100 µL of 0.9% saline solution (Aqupharm No1, Animalcare 
Ltd., York, UK), respectively. After 80 and 90 min to allow for biodistribution 
of the radiotracer, respectively, images were acquired using the Albira Si 
(Bruker) small-animal PET/SPECT/CT scanner at the University of Leeds, 
with animals placed prone and the field-of-view centred on the abdominal 
aorta. Mice were maintained at 1% anaesthesia during scanning, with 
temperature and respiration monitored throughout (Bruker). Following the 
20-min static and 90-min dynamic PET scans, respectively, a CT image was 
acquired for anatomic co-registration. PET/CT images were reconstructed 
using the maximum likelihood estimation maximisation algorithm (25 
iterations), yielding voxel dimensions of 0.5 mm3. 
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A cohort of animals received imatinib via oral gavage on days 14–15 
following mini-pump implantation. Matched controls received tap water, the 
solvent for imatinib. 
The imaging protocols implemented in the present study were based not 
only on the standard protocols at the University of Hull, but also on a number 
of well-established notions, as follows. In a study that involved toxicological 
evaluation of [18F]FLT in patients, blood-derived TACs showed a significant 
peak in activity within 5 min, followed by a gradual decrease to 110 min after 
radiotracer injection (Turcotte et al., 2007). Another study further showed a 
gradual decrease in the blood biodistribution of [18F]FLT in patients with 
cancer (Cysouw et al., 2017). Moreover, [18F]FLT uptake in proliferative 
lesions has been found to progressively increase over time to 80–100 min 
after radiotracer injection until eventual renal clearance (Lovinfosse et al., 
2019). Evaluation of the compartmental model of [18F]FLT kinetics, which 
describes the radiotracer’s uptake and retention over 120 min, has revealed 
that restricting PET data acquisition to 60 min leads to a loss in the accuracy 
of ROI-specific information. This study also revealed that curves 
corresponding to k3, which reflects [18F]FLT retention in tissues, are fairly 
stable between 90 and 120 min, with data acquisition beyond 90 min adding 
minimal value (Muzi et al., 2005). High repeatability of SUV quantification 
has also been demonstrated to occur when PET imaging is initiated at least 
60 min after radiotracer administration (Lodge et al., 2017). Keeping with 
these findings, dynamic PET imaging protocols commonly include short 
timeframes that progress to increasingly longer timeframes by the end of a 
90–120-min scan (Ukon et al., 2016). For these reasons, each dynamic scan 
was 90 min in duration, and short timeframes were implemented at the 
beginning of each dynamic scan in the present study to capture the peak 
activity of and any interesting fluctuations in the radiotracer immediately 
post-injection. 
2.4.1 PET/CT image analysis 
Animals with failed or paravenous radiotracer injection were excluded from 
the analyses. Three-dimensional isocontour ROIs incorporating the supra-
renal abdominal aortic area (between the renal arteries and diaphragm) 
were manually drawn on the reconstructed images using AMIDE v1.0.4 
software (Loening and Gambhir, 2003). The aortic ROI was constructed 
between the kidneys and anterior to the anterior border of the vertebral 
column based on the CT images including the most prominent PET signal in 
the 80- to 90-minute timeframe. For saline controls, the aortic ROI was 
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constructed between the kidneys, superior to the bladder, and anterior to the 
anterior border of the vertebral column based on the CT images. These 
ROIs had dimensions of 1.08 mm3 and contained 15 voxels. Incorporating 
mouse weights and injected radioactivity doses, the output statistics 
revealed the SUVmax and SUVmean across all frames. These values were 
used to generate time–activity curves (TACs) for ROIs in the abdominal 
aorta, spleen, kidneys, and urinary bladder. The SUVmax was the metric of 
choice for quantification of the aortic ROI to avoid partial volume effects of 
the adjacent kidneys and bladder, where high [18F]FLT signals were 
observed consistently. 
2.4.2 Generation of different ROI definitions for SUV analyses 
For the experiments conducted to assess the effect of different ROI 
definitions on the resulting SUVs, analyses were conducted based on two 
types of ROI definitions: (i) shape (manually drawn vs. fixed-size ROIs) and 
(ii) voxel threshold (the proportion of voxels included in the final SUV 
calculation).  
To address (i), the ellipsoid ROI-drawing tool was used to draw 4-mm 
ellipsoid ROIs in the abdominal aortic regions on images from both saline 
control and AngII AAA mice; these were the fixed-size ROIs. The size of the 
fixed-size ROI was chosen based on the maximum observed aneurysmal 
diameter of the aortae (approx. 3 mm). Therefore, the fixed-size ROIs were 
sufficiently large to contain the aneurysmal uptake without a deliberate 
attempt to align precisely with its contours, whilst also avoiding the inclusion 
of adjacent organs, such as the kidneys and urinary bladder. Manually 
drawn ROIs were generated using the 3D isocontour ROI-drawing tool to 
include as much of the abdominal aortic uptake as possible without including 
edges that may be subject to partial volume effects. For saline control 
images (i.e. the images that did not reveal abdominal aortic uptake of 
[18F]FLT), the aortic ROI was constructed between the kidneys, superior to 
the bladder, and anterior to the anterior border of the vertebral column based 
on the CT images, a similar approach to that described in section 2.4.1. To 
test the efficiency of each segmentation method, the time spent drawing 
each ROI was recorded. 
To address (ii), the following values were then determined for all fixed-size 
and manually drawn ROIs: SUVmean, SUV40, SUV50, SUV70, and SUV90, and 
SUVmax. The calculations for SUV40, SUV50, SUV70, and SUV90 included 
voxels that were equal to or greater than 40%, 50%, 70%, and 90% of the 
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highest value voxels, respectively, as defined in the AMIDE software manual 
(Leoning, 2014). For clinical relevance, the threshold values were chosen 
based on those implemented in previous studies (Dutour et al., 2009, 
Kahraman et al., 2011).  
2.5 Ex vivo [18F]FLT gamma counting 
Animals were anaesthetised with 5% isoflurane with an oxygen flow rate of 2 
L/min. [18F]FLT in 100 µL of 0.9% saline solution (Aqupharm No1, 
Animalcare Ltd., York, UK) was injected into the tail vein at the following 
doses (mean ± SD): C57BL6/J study, 6.07 ± 2.57 MBq (0.16 ± 0.07 mCi); 
AngII AAA study, 0.25 ± 0.32 MBq (0.01 ± 0.01 mCi). A significant difference 
in the injection doses is noted here. For the C57BL6/J study, the mice 
underwent in vivo PET imaging prior to their organs being used for ex vivo 
gamma counting; the PET imaging necessitated a sufficiently high 
radiotracer dose for the signals to be detected on the resultant images. For 
the AngII AAA study, the mice did not undergo prior in vivo PET imaging; 
thus, the injected dose was reduced to allow more animals to be included in 
a single experiment with a single delivery of [18F]FLT. This was possible 
owing to the high sensitivity of the Hidex gamma counter; furthermore, the 
reduced dose helped avoid oversaturation of the gamma ray detectors. 
Animals were recovered for 90 minutes and subsequently humanely culled 
by cervical dislocation under Schedule 1 of the UK (Scientific Procedures) 
Act 1986. Samples (blood, plasma, heart, spleen, kidneys, small and large 
intestines, supra-renal abdominal aorta, bone, and tail) were collected, 
weighed, and measured for radioactivity using the Hidex gamma counter. 
Importantly, blood was removed from the aortic lumen before it was placed 
in the gamma counter. All ex vivo biodistribution data were decay-corrected, 
and radioactivity counts were expressed as the percentage of injected dose 
per gram of tissue (%ID/g). The following equation was used for decay 
corrections (Multi-Agency Radiological Laboratory Analytical Protocols, 
2004) (Equation 2.1): 
%𝐼𝐷
𝑔
=
(
(
𝐶𝐺 − 𝐶𝐵
(
1 − 𝑒−𝜆∆𝑡𝑐
𝜆∆𝑡𝑐
) × 𝑒−𝜆∆𝑡𝑖
)
𝐴𝑖
) × 100
𝑀𝑆
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Equation 2.1 Normalised percentage of injected dose per gram of 
sample (%ID/g). CG, counting rate of sample (cps); CB, counting rate of 
blank/background (cps); λ, decay constant; Δtc, total counting time (s), 
Δti, time from injection to start of counting (s); Ai, injected activity 
(MBq); MS, mass of sample (g) 
2.6 Ex vivo [18F]FLT autoradiography 
Following a 90-minute delay for biodistribution (corresponding to the peak 
radiotracer uptake observed on in vivo PET images) and gamma counting, 
spleen, control aorta, and 14-day AngII AAA whole-organ samples were 
placed on a phosphor screen (PerkinElmer) covered with clear cellophane 
wrap. After overnight exposure, the imaging plates were scanned using the 
Cyclone Plus imager (PerkinElmer) at a resolution of 300 DPI. Images were 
processed using OptiQuant software (PerkinElmer). 
2.7 Western blotting 
Aortic tissue (supra-renal abdominal aortic segment only) was harvested 
under terminal isoflurane anaesthesia, snap-frozen in liquid nitrogen after 
phosphate-buffered saline perfusion, and stored at −80°C until use. Proteins 
were extracted using cell extraction buffer (FNN0011, Invitrogen) 
supplemented with Protease Inhibitor Cocktail (P8340, Sigma). The DC 
Protein assay kit (5000112, Bio-Rad) was used to quantify isolated proteins. 
The average yield was more than 3 mg of protein per aorta. Western blotting 
was performed for TK-1, a key enzyme expressed during DNA synthesis and 
the substrate for [18F]FLT, and the specific carriers responsible for the 
transport of both [18F]FLT and thymidine across the cell membrane: 
equilibrative nucleoside transporter (ENT)-1 and -2 and concentrative 
nucleoside transporter (CNT)-1 and -3. Each protein’s expression was 
compared to the expression of β-actin, a housekeeping protein expressed in 
all cells that is commonly used for data normalisation and as a loading 
control; this ensures that each well of the agarose gel contains consistent 
amounts of protein to be tested. For each protein, blots were conducted as 
per the manufacturer’s suggestions using 100 µg of protein per well. To 
create the running samples, β-mercaptoethanol (a reducing agent added to 
reduce disulphide bonds to irreversibly denature RNases) was added to 
laemmli sample buffer at a ratio of 1:4, and 3 parts of the target protein 
sample were then diluted into 1 part of this mixture. Antibodies and dilutions 
used were anti-TK-1, 1:500 (GTX113281; GeneTex, CA, USA); ENT-1, 
1:1000 (ab135756); ENT-2, 1:1000 (ab181192); CNT-1, 1:500 (ab192438); 
CNT-3, 1:500 (ab223085); and β-actin, 1:1000 (Ab8226; all Abcam, 
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Cambridge, UK). Proteins were detected using SuperSignal West Femto 
Maximum Sensitivity enhanced chemiluminescent substrate (ThermoFisher 
Scientific, Loughborough, UK). ImageJ 1.51k software was used to quantify 
the optical intensity of the bands relative to that of corresponding β-actin 
bands (Schneider et al., 2012). 
2.8 Statistical analyses 
All statistical analyses were performed using Origin 2017 software 
(OriginLab Corporation, Northampton, MA, USA). All graphs show the mean 
± the standard error of the mean (SEM) unless otherwise stated. There are 
two types of statistical tests: parametric and non-parametric. Parametric 
tests are typically used when the data to be analysed are normally 
distributed (i.e. the mean is a more accurate representation of the centre of 
the data) and sample sizes are large. Meanwhile, non-parametric tests are 
typically used when the data to be analysed are ‘distribution-free’ (i.e. the 
median more accurately represents the centre of the data) and when sample 
sizes are small. The Shapiro–Wilk test revealed that the data populations 
were normally distributed, unless indicated otherwise in the subsequent 
chapter; thus, parametric statistical tests were conducted to analyse all data. 
However, given the small sample sizes, non-parametric tests may be an 
appropriate alternative for statistical analysis, the results of which are 
presented in Appendix B. Histology, USS, and some gamma counting 
results were analysed using two-sampled t tests with Welch’s correction. 
Welch’s correction was implemented rather than Student’s t test as the 
former tends to be more reliable when sample sizes and variances are 
unequal (Glen, 2015). PET/CT, western blotting, and some gamma counting 
results were analysed using one-way analysis of variance with post hoc 
Bonferroni–Holm correction. Funding limitations generally restrict the 
number of animals that can be used; thus, it is important to implement a 
statistical test with maximum statistical power. Bonferroni–Holm correction is 
a uniformly more robust correction method than the Bonferroni method, as 
the former controls for the probability of type I error adjustments and the 
false discovery rate (Aickin and Gensler, 1996). The threshold for statistical 
significance was set at p < 0.05.  
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Chapter 3  
Results 
This chapter describes the outcomes of a series of experiments performed to 
answer critical questions about AAA-associated cell proliferation. Central to this 
thesis, PET/CT was undertaken with the aim of assessing the feasibility of using 
[18F]FLT to visualise and quantify cell proliferation in the AngII AAA model. This 
was followed up with Western blotting to directly test for biochemical markers of 
[18F]FLT activity, including the substrate and transporters of [18F]FLT. An 
attempt was also made to explore [18F]FLT PET/CT in a second model of AAA, 
and the findings of a pilot proof-of-concept therapeutic study are also described 
in this chapter. The overall experimental flow of all batches of ApoE-/- mice is 
illustrated in Figure 3.1. These ApoE-/- mice were used to obtain the results 
presented in sections 3.1, 3.3, 3.4, 3.5, and 3.7.   
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Figure 3.1 Different cohorts of ApoE-/- mice were used for different 
experiments.The age (weeks) of the mice at each stage is presented 
across the top of the figure.  
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3.1 Cell proliferation is detectable in murine AAA models 
AAA was first induced in mice by three methods: AngII infusion in ApoE-/- mice 
or CaCl2 or PPE application to the aorta in C57BL6/J mice (as described in 
section 2.1). The aortic tissues were harvested at 28 days post-induction of 
AAA for the AngII and CaCl2 models and 14 days post-induction of AAA for the 
PPE model (per the standard time points of the models). The tissues were then 
used for immunohistochemical staining for proliferative cells using an antibody 
raised against the cell proliferation marker Ki67, as described in section 2.2. 
Histological staining results from mouse aortic samples were analysed for the 
average proportion of Ki67-positive cells in three randomly selected regions 
containing proliferative cells (i.e. within the aortic wall), which was reflective of 
the proliferative activity. Aortae from control animals were compared against 
aortae from the three different aneurysm models. The abdominal aortic tissue 
from all three AAA models showed greater Ki67 staining compared to the 
control aortic tissue (Figure 3.2). 
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Figure 3.2 Aneurysm tissues show greater Ki67 staining than control 
aortic tissue. Representative histological images of Ki67-stained aortic 
tissue from the three AAA models: AngII, angiotensin II (blue); PPE, 
porcine pancreatic elastase (yellow); and CaCl2, calcium chloride (green). 
A single example control aorta is shown in red. Ki67 positivity is indicated 
by the brown colour, and a blue haematoxylin counterstain has been 
applied to aid visualisation.  
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On quantification, the proportions of Ki67-positive nuclei (mean±SEM) for the 
PPE-, AngII-, and CaCl2-induced AAA and saline control aortic tissues were 
81.4±1.1, 78.5±2.2, 68.7±1.0, and 0.11±0.01, respectively. Tissue from all the 
AAA models revealed a significant increase in the proportion of Ki67-positive 
nuclei in the aortic wall compared to that in the saline controls (all p<0.001) 
(Figure 3.3). The greatest proportions of Ki67-positive nuclei were observed in 
the PPE and AngII AAA models (both with significantly greater proportions 
compared to that in the CaCl2 model, p<0.001), whilst almost no proliferating 
cells were observed in the control aortic tissue. Overall, these data support the 
idea that cell proliferation occurs in the three major murine models of AAA. As 
the Ki67 staining was most pronounced in the AngII and PPE models, these 
were prioritised for use in the rest of the thesis. 
3.2 AngII AAA volume correlates with the proportion of Ki67-
positive nuclei 
In vivo USS imaging was performed in the AngII AAA animals eventually used 
for the Ki67 analysis. Evaluation by 3D USS revealed significant increases in 
aortic diameter and volume following 14-day AngII infusion compared to those 
in saline-infused controls. The aortic diameters (mean±SEM) were 1.39±0.06 
mm and 1.10±0.03 mm (p<0.001) and aortic volumes (mean±SEM) were 
15.34±0.80 mm3 and 11.16±0.73 mm3 (p<0.01) in the 14-day AngII AAA model 
(n=9) and saline controls (n=4), respectively (Figure 3.4). The proportion of 
Ki67-positive nuclei showed a positive correlation with aortic volume (p<0.05, 
Pearson’s r=0.85) (Figure 3.5). The results of the non-parametric statistical tests 
for these figures are presented in Appendix B. 
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Figure 3.3 PPE and AngII AAA tissue reveal the greatest proportions of 
Ki67-positive nuclei. Proportion of Ki67-positive nuclei in saline controls 
(n=3) and in the AngII (n=6), PPE (n=7), and CaCl2 (n=4) AAA models. *** 
p<0.001, ns: not significant on one-way ANOVA with post-hoc Bonferroni–
Holm correction. 
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Figure 3.4 Aortic volumes and diameters are larger in the AngII AAA 
model than in saline controls. Three-dimensional USS aortic 
reconstructions, volumes, and diameters in 14-day AngII AAA (n=9) vs. 
saline control aortae (n=4). ** p<0.01, *** p<0.001 on two-sample t test. 
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Figure 3.5 AngII AAA volume and the proportion of Ki67-positive nuclei 
are positively correlated. AngII AAA (n=6; blue). Pearson’s r=0.85, p<0.05. 
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3.3 Cell proliferation can be visualised and quantified using 
[18F]FLT PET/CT in the AngII AAA model 
Although the PPE and AngII models showed no significant difference in the 
proportion of Ki67-positive nuclei, the AngII model was chosen to implement for 
further experiments described in this thesis for two main reasons: (i) the surgery 
for AngII AAA is much simpler than that for PPE AAA and the experiments were 
performed at the University of Hull, where only basic surgical facilities were 
available; and (ii) AngII AAA consistently develops in the suprarenal region of 
the abdominal aorta, whereas PPE AAA develops in the infra-renal portion 
(Daugherty and Cassis, 2004). As [18F]-based PET radiotracers are excreted via 
the bladder, the signal in AngII AAA was anticipated to be further away from the 
signal due to bladder excretion than the signal in PPE AAA would be; hence, 
the AngII AAA was predicted to be easier to visualise and analyse.  
3.3.1 Animal survival decreased over the course of the experiment 
Twenty-two male ApoE-/- mice were enrolled in the saline vs. AngII PET/CT 
experiment performed at the University of Hull. Fourteen mice died at various 
time points during the experiment, as outlined in Figure 3.6. Images were only 
excluded from the subsequent SUV analysis in cases wherein the radiotracer 
injection was suboptimal, based on (i) judgment by the individual administering 
the injection and (ii) a lack of radiotracer signal in the inferior vena cava within 
the first 15 seconds of the scan. Meanwhile, Figure 3.7 presents Kaplan–Meier 
curves illustrating the proportion of surviving animals over the course of the 
experiment. All mice were harvested by terminal anaesthesia following the 28-
day PET scan. There was a greater proportion of surviving AngII AAA mice than 
surviving saline controls (Kaplan–Meier survival log rank p<0.01); all mice were 
then sacrificed in week 18. 
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Figure 3.6 Number of surviving animals decreased from 13 to 18 weeks of 
age. Flow of surviving animals that produced images for analysis through 
the experiment. 
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Figure 3.7 Number of surviving animals decreased from 13 to 18 weeks of 
the study period. Kaplan–Meier survival curves illustrate the proportions 
of surviving animals due to (A) all causes of death, (B) aortic rupture, and 
(C) PET-related deaths. All mice were sacrificed after the final PET/CT 
scan in week 18.  
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3.3.2  [18F]FDG uptake differs between saline controls and AngII 
AAA mice 
[18F]FDG is the most well-established radiotracer used in the clinic, particularly 
in the field of oncology, and is normally the first radiotracer to be considered for 
diagnostic imaging. Therefore, [18F]FDG was used for the initial experiment, the 
first preclinical PET study in collaboration with and performed at the University 
of Hull PET Imaging Centre. Starting with [18F]FDG allowed us to become 
familiar with and resolve any difficulties associated with the imaging protocol 
without any issues being attributed to [18F]FLT, a more novel radiotracer. 
For this initial experiment, ApoE-/- mice were divided into two treatment groups: 
saline or AngII infusions for 28 days (saline controls and AngII AAA mice, 
respectively). Dynamic PET/CT was performed on day 28 following implantation 
of the osmotic mini-pumps in the ApoE-/- mice. Radiotracer uptake was 
assessed in the IVC, myocardium, paraspinal region, and abdominal aorta. 
[18F]FDG uptake in the IVC was visualised within the first 15 s of each scan, 
reflecting the bolus radiotracer injection. This early signal confirmed successful 
intravenous radiotracer delivery and uptake after administration (Figure 3.8). 
[18F]FDG uptake was visualised in the myocardium of all mice, reflecting the 
typical basal myocardial energetics and confirming the radiotracer’s expected 
biodistribution. The myocardial [18F]FDG signal in the AngII AAA model was 
noticeably greater (Figure 3.9). Three-dimensional isocontour ROIs were 
manually drawn on the acquired images to extract SUVmax information over 
time, revealing the following values for myocardial ROIs (mean±SEM SUVmax 
80–90 min post-radiotracer injection, consistent with all other SUV calculations): 
1.91±0.00 (healthy controls, n=3); 5.06±0.20 (28-day AngII AAA, n=4) vs. 
1.92±0.02 (28-day saline control, n=6) (two-sample t test, p<0.001) (Figure 
3.10). Myocardial uptake of [18F]FDG in the 28-day AngII AAA model was 
greater than that in 28-day saline controls, as AngII infusion is also a model 
system for heart failure (Figure 3.10). 
  
- 67 - 
 
Figure 3.8 [18F]FDG uptake was visualised in the IVC at the beginning of 
each scan. Representative coronal-view PET images of dynamic IVC 
uptake of [18F]FDG from 4 to 14 s post-radiotracer injection. Colour scale 
bar indicates SUV thresholding to aid visualisation. 
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Figure 3.9 [18F]FDG uptake was visualised in the myocardium of all mice. 
Representative coronal-view PET/CT image of static myocardial uptake 
80–90 min post-radiotracer injection. Arrows indicate the myocardium. 
Colour scale bar indicates SUV thresholding to aid visualisation. 
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Figure 3.10 [18F]FDG uptake in the myocardium increased from 0 to 90 min 
post-[18F]FDG injection. (A) Time–activity curves of SUVmax and (B) 
absolute values of SUVmax. (C) Time–activity curves of SUVmean and (D) 
absolute values of SUVmean. SUVmax and SUVmean in (B) and (D) represent 
28-day [18F]FDG uptake in myocardial ROIs 80–90 min post-radiotracer 
injection of [18F]FDG in 28-day saline controls (n=6) and the 28-day AngII 
AAA model (n=4). 
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Uptake of [18F]FDG was also visualised in the paraspinal region in several mice. 
This was likely in response to standard animal handling practices and resultant 
stress induced in the animals (Fueger et al., 2006) (Figure 3.11).  
[18F]FDG uptake in the abdominal aortic region in the 28-day AngII AAA model 
was variable, with only two mice showing clear uptake in AAA (Figure 3.12).The 
TACs indicated that the radiotracer distributed to the abdominal aortic region at 
later time points of the scan in the mice that exhibited AAA uptake (Figure 3.13). 
Thus, 3D isocontour ROIs were drawn on images from the final time frame, 
which revealed the following values (mean±SEM 80–90 min post-radiotracer 
injection): SUVmean, 28-day saline controls (n=6) 0.07±0.004 vs. 28-day AngII 
AAA (n=4) 0.17±0.06 (two-sample t test, p=0.06); SUVmax, 28-day saline 
controls (n=6) 0.09±0.01 vs. 28-day AngII AAA (n=4) 0.24±0.08 (two-sample t 
test, p<0.05). A significant difference was noted in [18F]FDG abdominal aortic 
SUVmax between saline controls and 28-day AngII AAA mice (Figure 3.13). 
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Figure 3.11 [18F]FDG uptake was visualised in the paraspinal region of 
most mice. Representative sagittal-view PET/CT image of static paraspinal 
uptake 80–90 min post-radiotracer injection. Arrow indicates the 
paraspinal region. Colour scale bar indicates SUV thresholding to aid 
visualisation. 
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Figure 3.12 [18F]FDG uptake in the abdominal aorta was greater but 
variable in the 28-day AngII AAA model than in 28-day saline controls. 
Coronal-view PET/CT images of static 28-day abdominal aortic uptake of 
[18F]FDG 80–90 min post-radiotracer injection in all animals. Arrows 
indicate the abdominal aorta. Colour scale bars indicate SUV thresholding 
to aid visualisation. 
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Figure 3.13 [18F]FDG uptake in the abdominal aorta was variable in the 28-
day AngII AAA model than in saline controls. (A) Time–activity curves of 
SUVmax and (B) absolute values of SUVmax. (C) Time–activity curves of 
SUVmean and (D) absolute values of SUVmean. SUVmax and SUVmean in (B) 
and (D) represent 28-day [18F]FDG uptake in abdominal aortic ROIs 80–90 
min post-radiotracer injection in 28-day saline controls (n=6) and the 28-
day AngII AAA model (n=4). 
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3.3.3 [18F]FLT localises to expected regions of cell proliferation in 
control mice 
To establish reference data, healthy control mice were used to assess aortic 
[18F]FLT uptake and validate the biodistribution of [18F]FLT for the overall study. 
First, 90-min dynamic PET/CT revealed [18F]FLT uptake in the IVC within the 
first 15 s of each scan, reflecting the bolus radiotracer injection. This early 
signal confirmed successful intravenous radiotracer delivery and uptake after 
administration (Figure 3.14). 
[18F]FLT uptake was then visualised in the spleen of all mice, reflecting the role 
of the spleen as a reservoir of proliferative cells and confirming the radiotracer’s 
expected biodistribution (Figure 3.15). Three-dimensional isocontour ROIs were 
manually drawn on the acquired images to extract SUVmax information over 
time, revealing a mean±SEM SUVmax 80–90 min post-radiotracer injection of 
0.47±0.03 (n=3) in the spleen (Figure 3.16). These results were further 
confirmed by greater ex vivo uptake of [18F]FLT uptake in the spleen relative to 
the heart by gamma counting (mean±SEM: 186.99±9.99 vs. 86.82±17.18 
%ID/g, p<0.001), whilst the aorta exhibited comparable uptake to the heart 
(mean±SEM: 76.23±24.98 vs. 86.82±17.18 %ID/g, p=0.69), as expected (Figure 
3.17). Hepatic uptake of [18F]FLT was noted in some animals, but this was less 
consistently observed across all the animals than splenic uptake. Moreover, the 
low signal in the bone marrow was difficult to detect as a distinct region that 
could be easily delineated for further ROI analyses without significantly 
increasing the SUV threshold on the image visualisation software (AMIDE), 
which resulted in saturated signal across the image and reduced visibility of 
other ROIs. The heart and spleen were therefore used as negative and positive 
control organs, respectively, for all experiments involving [18F]FLT thereafter. 
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Figure 3.14 [18F]FLT uptake was visualised in the IVC at the beginning of 
each PET scan. Representative coronal-view PET images of dynamic IVC 
uptake of [18F]FLT from 4 to 14 s post-radiotracer injection. Colour scale 
bar indicates SUV thresholding to aid visualisation. 
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Figure 3.15 [18F]FLT uptake was visualised in the spleen of all healthy 
controls. Coronal-view PET/CT images of static splenic uptake of [18F]FLT 
80–90 min post-radiotracer injection. Arrows indicate the spleen. Colour 
scale bar indicates SUV thresholding to aid visualisation. 
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Figure 3.16 [18F]FLT uptake in the spleen increased from 0 to 90 min post-
[18F]FLT injection. Time–activity curves representing splenic uptake of 
[18F]FLT in healthy control mice (n=3). 
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Figure 3.17 Ex vivo [18F]FLT uptake in the spleen was greater than that in 
the heart and abdominal aorta in healthy control mice. Decay-corrected ex 
vivo [18F]FLT counts per mass units (n=3). *** p<0.001 on one-way ANOVA 
with post-hoc Bonferroni–Holm correction. 
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3.3.4 [18F]FLT uptake is observed in regions of cell proliferation in 
the AngII model of AAA 
For the AngII AAA experiments, dynamic PET/CT was performed on days 14 
and 28 following implantation of the osmotic mini-pumps. [18F]FLT uptake in the 
IVC was visualised within the first 15 s of each scan, reflecting the bolus 
radiotracer injection. Observation of this peak was facilitated by the short 2-s 
timeframes, which effectively revealed the early fluctuations in activity. The 
appearance of this signal at such an early time point of the scan confirmed 
successful intravenous radiotracer delivery and uptake after administration in 
the saline controls and AngII AAA mice (Figure 3.18).  
[18F]FLT uptake was consistently visualised in the spleen of all mice, as 
expected based on the baseline [18F]FLT experiment in healthy control mice 
(Figure 3.19). Three-dimensional isocontour ROIs were manually drawn on the 
acquired images to extract SUVmax information over time, revealing the following 
values for splenic ROIs (mean±SEM SUVmax 80–90 min post-radiotracer 
injection): 0.52±0.01 (14-day AngII AAA, n=5) vs. 0.52±0.00 (14-day saline 
control, n=5) (two-sample t test, p=0.48); 0.37±0.07 (28-day AngII AAA, n=3) vs. 
0.52 (28-day saline control, n=1) (Figure 3.20). Splenic uptake confirmed that 
[18F]FLT distributed to expected regions, as the spleen exhibits high basal 
proliferative activity. Interestingly, splenic uptake in the 28-day AngII AAA model 
was variable. 
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Figure 3.18 [18F]FLT uptake was visualised in the IVC at the beginning of 
each PET scan. Representative coronal-view PET images of dynamic IVC 
uptake of [18F]FLT from 4 to 14 s post-radiotracer injection. Colour scale 
bar indicates SUV thresholding to aid visualisation. 
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Figure 3.19 [18F]FLT uptake was visualised in the spleen of all mice. 
Representative coronal-view PET/CT image of static splenic uptake of 
[18F]FLT 80–90 min post-radiotracer injection. Arrow indicates the spleen. 
Colour scale bar indicates SUV thresholding to aid visualisation.  
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Figure 3.20 [18F]FLT uptake in the spleen increased from 0 to 90 min post-
[18F]FLT injection. Time–activity curves representing splenic uptake of 
[18F]FLT in (A) 14-day saline controls (n=5) and the 14-day AngII AAA 
model (n=5) and (B) 28-day saline control (n=1) and the 28-day AngII AAA 
model (n=3). 
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3.3.5  [18F]FLT uptake is observed in AngII AAA 
The dynamic PET data revealed that [18F]FLT distributed to the abdominal 
aortic region in the AngII AAA model in the later time points of the scan (Figure 
3.21). Static PET/CT images revealed that [18F]FLT uptake in the 14-day AngII 
AAA model in the final timeframe (80–90 min post-injection of [18F]FLT) was 
consistently enhanced compared to that in the saline controls (Figure 3.22).  
Three-dimensional isocontour ROIs were manually drawn between the renal 
arteries and diaphragm to incorporate the suprarenal abdominal aortic area in 
the final timeframe using AMIDE v1.0.4 software. The abdominal aortic ROI was 
constructed between the kidneys and anterior to the anterior border of the 
vertebral column based on the CT images, including the most prominent PET 
signal in the 80–90-min timeframe. Efforts were made to avoid including the 
edges of the region of [18F]FLT uptake to minimise partial volume effects due to 
signal spill-over from adjacent organs, notably the bladder. For saline controls, 
the aortic ROI was constructed between the kidneys, superior to the bladder, 
and anterior to the anterior border of the vertebral column based on the CT 
images; these ROIs had dimensions of 1.08 mm3 and contained 15 voxels 
(Figure 3.23). 
Incorporating mouse weights and injected radioactivity doses, output statistics 
revealed the SUVmax and SUVmean across all timeframes. These values were 
used to generate TACs for ROIs in the abdominal aorta. The late uptake of 
[18F]FLT in the 14-day AngII AAA model was also reflected in these 
corresponding TACs (Figure 3.24). As the [18F]FLT signal was the most 
prominent in the final timeframe, the SUVs were extracted from the final 
timeframe for analysis. The following values were obtained from the data of the 
14-day scan (mean±SEM 80–90 min post-radiotracer injection): SUVmax, 
0.010±0.002 (14-day saline controls, n=5) vs. 0.33±0.02 (14-day AngII AAA, 
n=5) (two-sample t test, p<0.001); SUVmean, 0.004±0.002 (14-day saline 
controls, n=5) vs. 0.25±0.02 (14-day AngII AAA, n=5) (two-sample t test, 
p<0.001) (Figure 3.24). The Shapiro–Wilk test revealed that the data of the 14-
day saline control group were not normally distributed. The results of the non-
parametric statistical test are presented in Appendix B. 
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Figure 3.21 [18F]FLT uptake in the abdominal aorta was visualised late in 
the 90-min scan. Representative coronal-view PET images of dynamic 
AAA uptake of [18F]FLT from 50 to 90 min post-radiotracer injection. 
Colour scale bar indicates SUV thresholding to aid visualisation. Arrows 
indicate the AAA.  
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Figure 3.22 [18F]FLT uptake in the abdominal aorta was greater in the 14-
day AngII AAA model than in saline controls. Coronal-view PET/CT 
images of static 14-day abdominal aortic uptake of [18F]FLT 80–90 min 
post-radiotracer injection in 14-day saline controls (n=5) and the 14-day 
AngII AAA model (n=5). Arrows indicate the abdominal aorta. Colour scale 
bars indicate SUV thresholding to aid visualisation. 
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Figure 3.23 Abdominal aortic ROIs for SUV analysis were constructed 
avoiding adjacent organs. Representative transverse-, coronal-, and 
sagittal-view static PET images and corresponding abdominal aortic ROI 
generation in (A) saline controls (yellow) and (B) 14-day AngII AAA mice 
(blue). 
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Figure 3.24 [18F]FLT uptake in the abdominal aorta was consistently 
greater in the 14-day AngII AAA model than in saline controls. (A) Time–
activity curves of SUVmax and (B) absolute values of SUVmax. (C) Time–
activity curves of SUVmean and (D) absolute values of SUVmean. SUVmax and 
SUVmean in (B) and (D) represent 14-day [18F]FLT uptake in abdominal 
aortic ROIs 80–90 min post-radiotracer injection in 14-day saline controls 
(n=5) and the 14-day AngII AAA model (n=5). *** p<0.001 on two-sample t 
test.  
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Of all mice with AngII AAA, [18F]FLT scans could be conducted at both the 14- 
and 28-day stages in only 3 mice, allowing for a comparison between early- and 
late-stage AngII AAA uptake of [18F]FLT. Data from the other animals were not 
available due to episodes of aneurysm rupture or unsuccessful radiotracer 
injection. All acquired static images of [18F]FLT uptake in the abdominal aortic 
regions of saline controls and 28-day AngII AAA mice in the 80–90-min 
timeframe are presented in Figure 3.25. The TACs for abdominal aortic ROIs 
following the 28-day PET/CT scans revealed greater [18F]FLT uptake in the 28-
day AngII AAA model than in the 28-day saline control (Figure 3.26). Similar to 
the analysis of the 14-day scan data, the SUVs were extracted from the final 
timeframe for analysis. Compared to [18F]FLT uptake in 14-day AngII AAA, 
reduced uptake was noted in 28-day AngII AAA (n=3) with a mean±SEM (80–90 
min post-radiotracer injection) SUVmax of 0.15±0.01 and SUVmean of 0.13±0.02. 
The single 28-day saline control mouse from which suitable data were retrieved 
presented with an SUVmax of 0.03 and SUVmean of 0.02, which were similar to 
the results of the 14-day saline controls (Figure 3.26); however, these data were 
not used for further analysis as they were insufficient for tests of statistical 
rigour. 
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Figure 3.25 [18F]FLT uptake in the abdominal aorta was greater in the 28-
day AngII AAA model than in the saline control. Coronal-view PET/CT 
images of static 28-day abdominal aortic uptake of [18F]FLT 80–90 min 
post-radiotracer injection in 28-day saline controls (n=1) and the 28-day 
AngII AAA model (n=3). Arrows indicate the abdominal aorta. Colour scale 
bars indicate SUV thresholding to aid visualisation. 
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Figure 3.26 [18F]FLT uptake in the abdominal aorta was consistently 
greater in the 28-day AngII AAA model than in the saline control. (A) 
Time–activity curves of SUVmax and (B) absolute values of SUVmax. (C) 
Time–activity curves of SUVmean and (D) absolute values of SUVmean. 
SUVmax and SUVmean in (B) and (D) represent 28-day [18F]FLT uptake in 
abdominal aortic ROIs 80–90 min post-radiotracer injection in 28-day 
saline controls (n=1) and the 28-day AngII AAA model (n=3). 
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3.3.6 Different ROI definitions may affect resultant SUVs 
Amide, the image visualisation and analysis software used for the PET/CT 
analysis in this study, includes parameters related to the ROI that can be 
modified by the user. A pilot investigation was conducted to determine whether 
changing these parameters in the software would influence the PET image 
analysis results. Fixed-size and manually drawn ROIs were generated and 
SUVmean, SUV40, SUV50, SUV70, SUV90, and SUVmax were determined, as 
described in section 2.4.2. The mean±SEM SUVmean, SUV40, SUV50, SUV70, 
SUV90, and SUVmax for both fixed-size and manually drawn abdominal aortic 
ROIs on all images are presented in Figure 3.27. In all images, the fixed-size 
and manually drawn abdominal aortic ROIs revealed the following mean±SEM 
values, respectively: SUVmean, 0.14±0.01 and 0.16±0.02; SUV40, 0.14±0.01 and 
0.16±0.02; SUV50, 0.14±0.02 and 0.16±0.02; SUV70, 0.16±0.02 and 0.16±0.02; 
SUV90, 0.19±0.02 and 0.17±0.02; and SUVmax, 0.20±0.02 and 0.18±0.03. 
Following a Shapiro–Wilk test that confirmed that the data were normally 
distributed (all p<0.05), paired t tests were conducted for all fixed-size and 
manually drawn ROI pairs of SUV thresholds, which revealed significant 
differences at all SUV thresholds (p<0.01) except at SUV70 (p=0.73). This 
indicated that the SUVs were correlated between fixed-size and manually drawn 
ROIs only when a 70% threshold was applied to the voxels included in the given 
ROI.  
The average times spent delineating the abdominal aortic regions were 
0.49±0.67 min and 1.54±0.54 min when implementing the fixed-size and 
manually drawn approaches, respectively; thus, fixed-size ROIs are less time-
consuming to generate, a finding that is likely important when tasked with 
analysing large datasets containing many images.  
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Figure 3.27 SUV70 corresponding to both fixed-size and manually drawn 
aortic ROIs exhibited no significant differences. The SUVmean, SUV40, 
SUV50, SUV90, and SUVmax were significantly different between fixed-size 
and manually drawn aortic ROIs. ** p<0.01, ns: not significant on paired t 
test. FS, fixed-size; MD, manually drawn 
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3.3.7  [18F]FLT uptake in the AngII AAA model may be localised to 
the aortic wall 
Using ImageJ 1.51k software, USS and PET/CT images were manually co-
registered. For the co-registration analysis, bony landmarks on CT and USS 
were aligned, which revealed [18F]FLT PET signal in the aortic wall in the AngII 
AAA model (Figure 3.28). 
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Figure 3.28 [18F]FLT uptake in the AngII AAA model may occur in the 
aortic wall. Representative transverse-view ultrasound, [18F]FLT PET/CT, 
and fused ultrasound–PET/CT images. Short arrow, aortic lumen; long 
arrow, remodelling aortic wall. 
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3.4 Ex vivo [18F]FLT uptake is greater in AngII AAA than in 
saline control aortae 
As described previously in section 3.3.3, the baseline [18F]FLT biodistribution 
study demonstrated high uptake in the spleen and low uptake in the aorta and 
heart; the aorta exhibited comparable uptake to the heart, whilst the spleen 
exhibited greater uptake relative to the heart. Therefore, the heart and spleen 
were used as negative and positive control reference tissues, respectively, 
going forward. To confirm the tissue-specific origin of the [18F]FLT signal 
observed on PET/CT in the abdominal aortic ROI, ex vivo gamma counting was 
performed using whole organs from 14-day AngII AAA mice and saline controls. 
Uptake in the aorta and spleen were then normalised to uptake in the heart to 
control for mouse-to-mouse variability. [18F]FLT counts in the abdominal aorta 
relative to the heart in the 14-day AngII-infused mice (n=9) were significantly 
increased compared to those in saline controls (n=4) (mean±SEM: 3.30±1.01 
vs. 0.37±0.14 %ID/g, p<0.05) (Figure 3.29). The Shapiro–Wilk test revealed that 
the data of the 14-day AngII AAA group were not normally distributed. The 
results of the non-parametric statistical test are presented in Appendix B.  
Moreover, a pilot attempt was made to perform ex vivo autoradiography of 
[18F]FLT uptake in whole-organ samples. Although the number of samples was 
small, greater [18F]FLT uptake in the aneurysmal aorta compared to that in the 
control aorta was observed, as expected based on the ex vivo biodistribution 
results. 
3.4.1 Aortic [18F]FLT uptake is correlated with aortic volume 
A significantly positive correlation was noted between [18F]FLT uptake on ex 
vivo gamma counting and aortic volume on in vivo USS (p<0.05, Pearson’s 
r=0.67) (Figure 3.30). 
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Figure 3.29 Ex vivo [18F]FLT uptake in the abdominal aorta was greater in 
the 14-day AngII AAA model than in 14-day saline controls. Decay-
corrected ex vivo [18F]FLT counts per mass units. (A) All organs. (B) 
Uptake in the spleen and abdominal aorta normalised to uptake in the 
heart in the 14-day AngII AAA model (n=9) and 14-day saline controls 
(n=4). * p<0.05 on two-sampled t test with Welch’s correction. 
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Figure 3.30 Aortic volume is positively correlated with [18F]FLT uptake. 
Correlation between aortic volume and ex vivo [18F]FLT counts in AngII 
AAA (blue, n=9). Pearson’s r=0.67, p<0.05. 
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3.5 Expression of key molecules involved in [18F]FLT 
metabolism are upregulated in the AngII AAA model 
The [18F]FLT PET/CT data presented in section 3.3 suggest increased 
abdominal aortic proliferative activity in the 14-day AngII AAA model compared 
to that in control animals, which diminishes at the 28-day time point. To further 
investigate the change in [18F]FLT signal observed between 14- and 28-day 
AngII AAA, an independent cohort of mice was divided into 4 groups, and 
aortae were harvested: baseline group (n=3), containing ApoE-/- mice; saline 
control group (n=3), containing ApoE-/- mice that received saline infusions for 14 
days; 14-day AngII AAA group (n=3), containing ApoE-/- mice that received 
AngII infusions for 14 days; and 28-day AngII AAA (n=3), containing ApoE-/- 
mice that received AngII infusions for 28 days. This was followed by western 
blotting for (i) TK-1, the key substrate of [18F]FLT, and (ii) the nucleoside 
transporters that carry [18F]FLT into the cell: ENT-1, ENT-2, CNT-1, and CNT-3. 
The response of these proteins to AngII-induced AAA is unknown. 
3.5.1 Expression of the substrate of [18F]FLT is increased in the 
AngII AAA model  
Consistent with [18F]FLT uptake observed using PET/CT, the TK-1 band 
intensity was increased after 14-day AngII infusion compared to that after saline 
control and 28-day AngII infusion (mean±SD TK-1:β-actin band intensities: 
2.45±0.24, 0.34±0.02, and 1.07±0.07, respectively; all p<0.001) (Figure 3.31). 
The results of the non-parametric statistical test are presented in Appendix B. 
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Figure 3.31 TK-1 expression was the greatest in 14-day AngII AAA. (A) 
Representative TK-1 western blots. (B) Quantitative analysis. TK-1 band 
intensity was normalised to β-actin band intensity. *** p<0.001, ns: not 
significant on one-way analysis of variance with post-hoc Bonferroni–
Holm correction. 
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3.5.2 Expression of [18F]FLT transporters is increased in the AngII 
AAA model  
The ENT-1 band intensity was increased after 14-day AngII infusion compared 
to that after saline control and 28-day AngII infusion (mean±SD ENT-1:β-actin 
band intensities: 2.74±0.09, 0.10±0.06, and 1.45±0.11, respectively; all 
p<0.001) (Figure 3.32). The Shapiro–Wilk test revealed that the data of the 
saline control group were not normally distributed. The intensity of the ENT-2 
band was also increased after 14-day AngII infusion compared to that after 
saline control and 28-day AngII infusion (mean±SD ENT-2:β-actin band 
intensities: 2.66±0.13, 0.29±0.00, and 1.68±0.04, respectively; all p<0.001) 
(Figure 3.33). Keeping with a similar pattern, the CNT-1 band intensity was 
increased following 14-day AngII infusion compared to that following saline 
control and 28-day AngII infusion (mean±SD CNT-1:β-actin band intensities: 
4.06±0.45, 0.24±0.02, and 1.53±0.09, respectively; all p<0.001) (Figure 3.34). 
Finally, the intensity of the CNT-3 band was increased after 14-day AngII 
infusion compared to that after saline control and 28-day AngII infusion 
(mean±SD CNT-3:β-actin band intensities: 3.69±0.70, 0.40±0.21, and 
2.03±0.44, respectively; all p<0.001) (Figure 3.35). Overall, the key proteins 
tested that play a role in [18F]FLT metabolism were upregulated in 14-day AngII 
AAA tissue compared to 28-day AngII AAA and saline control tissue. For 
reference, all the tested proteins were found to be expressed in tissue from a 
saline control spleen, which was expected as the spleen contains proliferative 
cells. The differences in protein expression were insignificant between baseline 
and saline control aortae for all the tested proteins. The results of all non-
parametric statistical tests corresponding to these findings are presented in 
Appendix B. 
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Figure 3.32 ENT-1 expression was the greatest in 14-day AngII AAA. (A) 
Representative ENT-1 western blots. (B) Quantitative analysis. ENT-1 band 
intensity was normalised to β-actin band intensity. *** p<0.001, ns: not 
significant on one-way analysis of variance with post-hoc Bonferroni–
Holm correction. 
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Figure 3.33 ENT-2 expression was the greatest in 14-day AngII AAA. (A) 
Representative ENT-2 western blots. (B) Quantitative analysis. ENT-2 band 
intensity was normalised to β-actin band intensity. *** p<0.001, ns: not 
significant on one-way analysis of variance with post-hoc Bonferroni–
Holm correction. 
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Figure 3.34 CNT-1 expression was the greatest in 14-day AngII AAA. (A) 
Representative CNT-1 western blots. (B) Quantitative analysis. CNT-1 
band intensity was normalised to β-actin band intensity. *** p<0.001, ns: 
not significant on one-way analysis of variance with post-hoc Bonferroni–
Holm correction. 
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Figure 3.35 CNT-3 expression was the greatest in 14-day AngII AAA. (A) 
Representative CNT-3 western blots. (B) Quantitative analysis. CNT-3 
band intensity was normalised to β-actin band intensity. *** p<0.001, ns: 
not significant on one-way analysis of variance with post-hoc Bonferroni–
Holm correction. 
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3.6 Cell proliferation is difficult to visualise and quantify using 
[18F]FLT PET/CT in the PPE AAA model 
The PPE model of AAA is a well-established non-progressive disease model 
that is less likely to rupture than the AngII infusion model (Senemaud et al., 
2017). As one of the commonly studied murine models of AAA and the model 
that showed the greatest proportion of Ki67-positive nuclei (reported in section 
3.1), aortic volumes and [18F]FLT uptake were explored in the PPE AAA model 
to investigate if the findings from the AngII model could be replicated in a 
second model.  
3.6.1 Aortic volumes and diameters in the PPE AAA model are 
larger than those in sham controls 
Evaluation by 3D USS revealed the expected significant increases in aortic 
diameter (p<0.05) and volume (p<0.05) 14 days post-PPE application 
compared to baseline and sham-operated controls. The aortic diameters were 
1.66±0.53 mm (mean±SEM) and 0.52 mm and aortic volumes were 18.72±5.47 
mm3 (mean±SEM) and 2.70 mm3 in the 14-day PPE model (n=3) and 14-day 
sham control (n=1), respectively (Figure 3.36). 
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Figure 3.36 Aortic volume and AP diameters were greater in the 14-day 
PPE AAA model than in sham controls. Aortic volumes and AP diameters 
based on 3D USS of 14-day PPE AAA (n=3) vs. 14-day sham control aortae 
(n=1). ns: not significant on two-sample t test. 
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3.6.2 In vivo [18F]FLT uptake is variable in the PPE AAA model 
Static PET/CT images revealed that [18F]FLT uptake in the 14-day PPE AAA 
model 80–95 min post-injection of [18F]FLT was variable and noisy due to 
uptake in regions surrounding the abdominal aorta, such as areas of the bowel, 
leading to inconclusive evidence of [18F]FLT uptake in PPE AAA (Figure 3.37). 
Additionally, multiple hotspots of diffuse radiotracer uptake were noted on the 
PET images of the abdominal region, making it difficult to confidently delineate 
the abdominal aorta. This background uptake was not observed in the AngII 
AAA model, leading to the suspicion that these hotspots in the abdominal and 
bowel areas resulted from the method of PPE application. For this method, the 
mice are laparotomised, and 10 µL of PPE is applied to the abdominal aorta 
using a syringe. The [18F]FLT signal may relate to post-surgical changes in the 
abdomen involving the formation of adhesions, which can occur following any 
laparotomy. 
3.6.3 Ex vivo [18F]FLT uptake in PPE AAA is similar to that in sham 
control aortae 
Ex vivo gamma counting was then performed, as per section 2.5. The 
experiment revealed no significant difference in [18F]FLT counts in the 
abdominal aorta relative to the heart between the 14-day PPE AAA and 14-day 
sham control (Figure 3.38). These results suggested that there was no 
significant uptake in the AAA. 
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Figure 3.37 [18F]FLT uptake in the abdominal aorta was difficult to 
visualise in the 14-day PPE AAA model. Coronal-view PET/CT images of 
static 14-day abdominal aortic uptake of [18F]FLT 80–95 min post-
radiotracer injection in all animals. Arrows indicate the abdominal aortic 
region. Colour scale bars indicate SUV thresholding to aid visualisation. 
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Figure 3.38 Ex vivo [18F]FLT uptake in the abdominal aorta was similar in 
PPE AAA and sham control aortae. Decay-corrected ex vivo [18F]FLT 
counts per mass units (A) All organs. (B) Uptake in the spleen and 
abdominal aorta normalised to uptake in the heart in PPE AAA (n=3) and 
sham control (n=1) aortae. 
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3.7 [18F]FLT PET/CT might be useful to assess a therapeutic 
response in the AngII AAA model 
Finally, [18F]FLT PET/CT was used in a proof-of-concept exploratory experiment 
to determine if the response to an anti-proliferative tyrosine kinase inhibitor 
commonly used as a cancer therapeutic (imatinib) could be detected in the 
AngII AAA model. Considering the high rupture rate of the AngII AAA model and 
economic feasibility, 15 mice received AngII infusions. Aortic rupture occurred in 
5 mice within 12 days of AngII treatment. Three-dimensional USS after 12-day 
AngII infusion revealed that aneurysms developed in all surviving mice; 6 of the 
10 mice presented with aneurysms that were neither dissecting nor ectatic, 
which were categorised as ‘high priority’ for PET/CT imaging. The remaining 4 
mice with smaller aneurysms were categorised as ‘low priority’ for PET/CT 
imaging. 
Pre-treatment [18F]FLT PET/CT was performed on day 13 of AngII infusion, 
during which 2 of the high-priority mice and 2 of the low-priority mice died 
following [18F]FLT injection. The PET/CT data acquired from 3 of the 4 mice that 
survived to produce follow-up data revealed notable [18F]FLT uptake in the AAA 
region. Three-dimensional isocontour ROIs revealed a mean±SEM (n=3) 
SUVmax of 0.19±0.01 and SUVmean of 0.18±0.01. All mice were then 
administered 3 doses of imatinib or tap water (as the vehicle treatment) via oral 
gavage before undergoing follow-up PET/CT on day 15 of AngII infusion. Post-
imatinib PET data revealed a mean±SEM (n=2) SUVmax of 0.02±0.0 and 
SUVmean of 0.02±0.0; these were significantly decreased compared to the pre-
treatment values (p<0.001 and p<0.001, respectively). [18F]FLT uptake in AAA 
decreased after 3 doses of imatinib, reflecting an anti-proliferative response that 
was detectable in the early stage of AAA progression using PET/CT. 
Meanwhile, matched tap water treatment resulted in no significant change in 
[18F]FLT uptake, lending support to the imatinib data (n=1: SUVmax of 0.23 and 
SUVmean of 0.21, respectively, compared to pre-treatment) (Figure 3.39).  
Ex vivo gamma counting was then performed. [18F]FLT counts in the abdominal 
aorta relative to the heart in the AngII AAA mice that received imatinib were 
decreased compared to that in the AngII AAA mouse that received vehicle 
treatment (mean±SEM: 23.89±8.57 vs. 51.55 %ID/g) (Figure 3.40). 
  
- 111 - 
 
Figure 3.39 [18F]FLT uptake in AngII AAA decreased following imatinib 
treatment. Coronal-view PET/CT images of static abdominal aortic uptake 
of [18F]FLT 80–100 min post-radiotracer injection pre- and post-treatment 
with imatinib or vehicle (tap water). Arrows indicate the abdominal aorta. 
Colour scale bars indicate SUV thresholding to aid visualisation. 
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Figure 3.40 Ex vivo [18F]FLT uptake in AngII AAA was reduced following 
imatinib treatment than that following vehicle treatment. Ex vivo [18F]FLT 
uptake in the spleen and abdominal aorta normalised to uptake in the 
heart following vehicle (n=1) and imatinib (n=2) treatment. 
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3.8 Summary and conclusions 
This chapter presented critical experiments conducted to explore if [18F]FLT 
uptake could be observed in experimental murine models of AAA. The 
proportion of Ki67-positive nuclei was shown to be the greatest in the PPE and 
AngII AAA models and is correlated with aortic volume in the AngII AAA model. 
Uptake of [18F]FDG was investigated in saline controls and the AngII AAA 
model, revealing variable aneurysmal uptake. Myocardial [18F]FDG uptake was 
observed in all animals, with significantly greater uptake in AngII AAA mice. 
Furthermore, the uptake of [18F]FLT was explored in healthy controls to 
establish control data and validate the use of [18F]FLT as a cell proliferation 
marker in a non-disease control model. Finally, and most importantly, [18F]FLT 
PET/CT appears to be a feasible modality to visualise and quantify cell 
proliferation in the AngII AAA model. This was further validated by ex vivo 
[18F]FLT uptake in AAA, which was correlated with aortic volume 14 days post-
induction of AAA. The expression levels of TK-1, the substrate of [18F]FLT, and 
the transporters that carry [18F]FLT into cells are also increased in the 14-day 
AngII AAA model, mirroring the in vivo [18F]FLT PET data. The [18F]FLT results 
in the AngII model could not be positively replicated in the PPE model. An 
exploratory study demonstrated that [18F]FLT PET/CT may be used to visualise 
a decrease in the proliferative signal in the AngII AAA model following 3 doses 
of imatinib; however, these results must be interpreted with caution owing to the 
small sample sizes. 
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Chapter 4 Discussion 
The main objective of this thesis was to assess the feasibility of using 
[18F]FLT PET/CT to visualise and quantify cell proliferation in the AngII AAA 
mouse model. In 14-day AngII-induced AAA compared to 28-day AngII-
induced AAA and saline-infused controls, the [18F]FLT PET signal was found 
to be significantly increased, along with greater [18F]FLT counts in excised 
aortic tissue, which correlate with aortic volume. The expression of the 
[18F]FLT substrate TK-1 and [18F]FLT transporters ENT-1, ENT-2, CNT-1, 
and CNT-3 are also increased in 14-day AngII AAA than in 28-day AngII 
AAA and saline controls. These findings collectively suggest an early period 
of cell proliferation in the AngII AAA murine model, which is detectable using 
PET/CT. Some key findings are discussed in this chapter, including the 
evidence of cell proliferation and an early active growth phase, the 
correlation between aortic volume and cell proliferation, and features of 
PET/CT image analysis that may be improved to generate even more robust 
results. These key aspects are further discussed in the context of clinical 
applications to highlight the long-term translatability of the findings of this 
thesis. This chapter concludes with a discussion of areas for future research 
and a brief summary. 
It is well known that the AngII AAA mouse model exhibits a number of 
features that pose a challenge to the type of experiments described in this 
thesis, wherein large numbers of subjects are required to optimally utilise 
both the expensive bespoke radiotracer production and time on the PET/CT 
scanner: (i) the AngII model has a high rate of mortality due to aneurysm 
rupture, with most deaths occurring within the first 7 days following mini-
pump implantation (Cao et al., 2010); (ii) a proportion of animals will not 
respond to AngII infusion to form an aneurysm (i.e. non-responders); and (iii) 
tail vein injection for radiotracer delivery in the AngII model was more 
challenging than in wildtype C57BL6/J mice, and some animals needed to 
be excluded because of failure of radiotracer delivery via the fragile and 
poorly accessible tail vein. To overcome (i–iii), the sample sizes at the start 
of the experiments were overestimated to take account of estimated losses 
due to aortic rupture, non-response, and technical problems. However, to 
achieve this, ApoE-/- mice had to be bought from commercial suppliers, as 
sufficient numbers could not be guaranteed from the University’s internal 
breeding programme. During the project, the main supplier discontinued 
breeding in the UK, and the animals had to be imported from the EU, posing 
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a significant economic challenge. Therefore, the sample sizes in this study 
were relatively small.  
4.1 Histological evidence of cell proliferation in AAA 
The first finding in the present study was evidence of a significantly 
increased proportion of cells with Ki67-positive nuclei in the suprarenal 
abdominal aortic wall from AngII-infused ApoE-/- mice compared to those 
from saline-infused controls with a relative difference of approx. 200%, which 
was positively correlated with aortic volume. This result indicated that cell 
proliferation is indeed upregulated in the AngII AAA model. This is an 
important finding to justify the use of an expensive tool like [18F]FLT PET/CT 
later in the study to test its feasibility in visualising and quantifying the 
observed cell proliferation. Ki67 staining is a well-established method to 
identify proliferative cells, and [18F]FLT is a marker of cell proliferation; in line 
with this, the correlation between [18F]FLT uptake and Ki67 positivity has 
been demonstrated in several tumour models (Grierson and Shields, 2000, 
Salskov et al., 2007). Ki67 is an extensively utilised marker for cell 
proliferation in laboratory and clinical studies, and its utility has been 
demonstrated in detecting proliferative activity in numerous cell types in 
various diseases. In the present study, significantly greater proportions of 
Ki67-positive nuclei were observed in tissues from three different AAA 
murine models than that from saline control tissue. This is in line with reports 
of increased Ki67 positivity in patients with AAA, reflecting VSMCs, 
endothelial cells, and macrophages based on combined staining for anti-α-
smooth muscle actin, cluster of differentiation (CD)-31, and CD68, 
respectively (Cafueri et al., 2012, Ryer et al., 2015). In terms of other non-
aneurysmal diseases, positive Ki67 expression is observed in systemic 
lupus erythematosus in association with disease activity (Hudspeth et al., 
2019), and positive Ki67 staining has also been noted in human and ApoE-/- 
murine atherosclerotic lesions, wherein the proliferating cells are suggested 
to be rich in macrophages and inflammatory cell infiltrates in the active 
growth phase of lesion development, eventually leading to localised 
apoptosis; however, the exact cell types contributing to the disease process 
remain mostly uncharacterised, similar to that in AAA (Lhoták et al., 2016). 
The heightened Ki67 positivity observed in the present study is also similar 
to that observed in human prostate carcinoma (Keshgegian et al., 1998, 
Claudio et al., 2002), follicular thyroid tumours (Mu et al., 2018), severe 
cervical cancer lesions (Silva et al., 2017), and breast cancer (Qiu et al., 
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2019). Therefore, the positive Ki67 data in the AngII AAA mouse samples 
suggest that there is indeed a proliferative phase in the AngII AAA model.  
4.2 Expression of key players in the [18F]FLT mechanistic 
pathway 
In line with the Ki67 data, the level of TK-1 expression was significantly 
increased in 14-day AngII AAA tissue than in saline control tissue with a 
relative difference of approximately 151%, followed by a decrease to a 78% 
relative difference in 28-day AngII AAA tissues, supporting the notion that 
cell proliferation is an event that occurs during the progressive phase of AAA 
in this model. [18F]FLT is a substrate for cytoplasmic TK-1, which has been 
demonstrated as a proliferation biomarker in leukaemia, Hodgkin’s and non-
Hodgkin’s lymphoma, lung carcinoma, and breast cancer, amongst other 
cancers (Zhou et al., 2013). Furthermore, studies of TK-1 expression in 
cancer have revealed its associations with tumour stage, histological grade, 
metastasis, size, and distant and local recurrence (He et al., 2000, Mao et 
al., 2002, He et al., 2006, Aufderklamm et al., 2012, Nisman et al., 2013). 
The (i) overexpression of TK-1 and (ii) its correlation with the Ki67 
proliferation index have also been demonstrated in various cancers (Mao et 
al., 2005, Chen et al., 2013, Bagegni et al., 2017).  
In addition to TK-1, the expression levels of the equilibrative and 
concentrative transporters ENT-1, ENT-2, CNT-1, and CNT-3 were found to 
be significantly increased in 14-day AngII AAA tissue compared to those in 
saline control tissues with relative differences of 160–185%, followed by a 
decrease to 45–90% relative differences in 28-day AngII AAA tissues. These 
transporters contribute to nucleoside homeostasis, and as they are 
responsible for the cellular uptake of some nucleoside-based drugs, they 
may be valuable in nucleoside-derived therapy (Molina-Arcas et al., 2009, 
Jiraskova et al., 2018). These nucleoside transporters are also reported to 
influence [18F]FLT uptake; Paproski et al. previously characterised [18F]FLT 
transport by these transporters in cancer cell lines and demonstrated that 
they contribute to [18F]FLT uptake, with ENT-1 showing the most significant 
expression (Paproski et al., 2008, Paproski et al., 2010). There is an 
established association between [18F]FLT uptake and proliferation- or 
thymidine-associated marker expression in various cancers, some of which 
include Ki67 expression in breast cancer, CD8 and Ki67 expression in 
metastatic prostate cancer, Ki67 and TK-1 expression in lung cancer, and 
proliferating cell nuclear antigen and TK-1 expression in fibrosarcoma; these 
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associations are interesting to draw parallels with correlations amongst 
[18F]FLT uptake and the expression of TK-1, ENT-1, ENT-2, CNT-1, and 
CNT-3 observed in AAA (Barthel et al., 2003, Brockenbrough et al., 2011, 
Woolf et al., 2014, Scarpelli et al., 2019). Furthermore, concomitant 
malignancies have been reported in up to 14% of AAA cases, of which most 
involve colorectal cancer (Jibawi et al., 2011). Although it might be ambitious 
to propose that cancers and AAA involve similar proliferative mechanisms, 
further studies are warranted to determine whether significant commonalities 
exist between their pathogeneses. Considering our current understanding of 
[18F]FLT in cancer progression and proliferation, the findings of these 
proteins being upregulated and expressed in AngII AAA tissue support the 
notion of proliferation occurring at an early stage of AAA development.  
4.3 [18F]FLT uptake in the AngII AAA model 
Given the significantly high proportion of Ki67-positive nuclei at the end of 
the period of AngII infusion (28 days post-implantation of the mini-pump), 
[18F]FLT PET/CT was planned to be performed on day 28. As this 
experiment was complex and expensive, the decision was made to perform 
an additional scan at a second time point (i.e. day 14) to identify if there was 
a change in radiotracer uptake over time in the AngII AAA disease course. In 
this study, the uptake of [18F]FLT in AAA was successfully demonstrated for 
the first time. Interestingly, the uptake significantly decreased by a relative 
difference of 55% between days 14 and 28 of the model, suggesting that 
there may be a decrease in proliferative activity in the late stage of AAA. 
Furthermore, the alignment of [18F]FLT results with Ki67 staining data and 
supporting evidence from Western blotting for key players in the [18F]FLT 
mechanistic pathway support the PET/CT observations and raise the 
potential of using [18F]FLT as a tool to observe proliferative activity in in vivo 
model systems or indeed in humans.  
As described in section 1.3.5, AAA formation and progression rely on 
multiple contributing factors. These include changes in the mechanical 
properties of the vessel wall, such as wall stress and elasticity; inflammatory 
cell infiltration of the aortic wall; increased autoimmunity; enhanced oxidative 
stress; vascular remodelling; degradation of the ECM; and microcalcification. 
This multifactorial nature corresponds to many cells contributing to the AAA 
pathophysiology, such as lymphocytes, mast cells, macrophages, ECM 
proteins, VSMCs, and endothelial cells, amongst others (Wang et al., 2014, 
Kuivaniemi et al., 2015, Sun et al., 2018). Reports of the precise cell types 
that may contribute to the early-stage proliferative signal are largely 
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inconclusive, owing to the wide variety of implicated cell types and difficulties 
in accurately identifying them in vivo using antibody staining. Although the 
experiments presented in this thesis do not concretely prove that the 
proliferative signal originates from VSMCs, the findings are in line with 
reports of VSMC apoptosis, medial wall thinning, and degeneration in late-
stage AAA, which are critical for aortic dilatation and rupture (Lopez-
Candales et al., 1997, Henderson et al., 1999, Ailawadi et al., 2009, Riches 
et al., 2013, Salmon et al., 2013, Clement et al., 2019, Quintana and Taylor, 
2019). These events are associated with VSMC phenotypic switching early 
in AAA development. The reduced density of VSMCs in late-stage AAA is 
suggested to be the result of apoptosis, evidenced by the observation of 
apoptotic VSMCs in the medial layer of AAA in humans (Rowe et al., 2000, 
Kuivaniemi et al., 2015). When the rate of VSMC apoptosis exceeds the rate 
of VSMC proliferation, the number of SMC layers in the aortic wall 
decreases, eventually leading to rupture. When VSMC proliferation is 
promoted via anti-inflammatory treatment with interleukin-10, the 
degradation of SMCs is inhibited, leading to a delay in the development of 
AAA in rabbits (Zhu et al., 2019). Aneurysm growth is also inhibited in ApoE-
/- mice following treatment with the xanthine derivative KMUP-3, which 
inhibits AAA phenotypic switching and apoptosis (Lai et al., 2020). Moreover, 
studies have demonstrated VSMC proliferation and the role of 
dedifferentiated medial VSMCs in neo-intimal development following 
vascular injury (Herring et al., 2014, Roostalu et al., 2018). These findings 
propose an important role for VSMCs in AAA development; however, further 
experiments are warranted to determine the precise contributions of other 
cell types and regardless of the implicated cell types, it is suggested that the 
pathobiology differs between early- and late-stage AAA.  
The overall findings of an increase in proliferation-associated biomarkers at 
14 days followed by a decrease at 28 days point to an active period of cell 
proliferation early in the AngII-infused AAA disease course that then leads to 
replicative senescence and reduced proliferative activity late in the disease 
course. ‘Replicative senescence’ was first described in the context of human 
fibroblasts in culture and reflects the process that limits the proliferative 
activity of cells, as cells have a finite life span in which division occurs 
(Campisi, 1997). Cell senescence has been reported in patients with AAA 
and patients manifesting risk factors of AAA (Liao et al., 2000, Gacchina et 
al., 2011), and senescence can also progress to apoptosis (Thompson et al., 
1997). In addition, accelerated replicative senescence comprises a distinct 
phenotype of VSMCs in human AAA compared to that of VSMCs in the non-
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aneurysmal inferior mesenteric artery, indicating that senescence may play a 
role in the VSMC reduction that is specifically observed in AAA (Liao et al., 
2000, Riches et al., 2018). Furthermore, this late-stage VSMC reduction may 
reflect the increased accumulation of ECM degradative proteins, the 
production of which is stimulated by VSMCs, as well as endothelial cells, 
adventitial fibroblasts, and inflammatory cells that are adherent to the ECM. 
In AAA, the amount of proteins that confer aortic wall integrity, such as 
collagen and elastin, is reduced compared to that in normal aortae (Lin et al., 
2018, Quintana and Taylor, 2019). An imbalance between proteolytic 
enzymes, such as MMPs, and their inhibitors contributes to this reduction; 
correspondingly, various MMPs have been shown to be produced by 
VSMCs, and a marked increase in MMP expression has then been shown to 
be associated with a reduction in VSMCs with AAA disease progression 
(Knox et al., 1997, Mao et al., 1999, Kadoglou and Liapis, 2004, Fanjul-
Fernández et al., 2010, Courtois et al., 2013, Lin et al., 2018, Quintana and 
Taylor, 2019). This imbalance leads to a disruption in the equilibrium 
between ECM synthesis and degradation, which then influences the course 
of expansion and rupture of AAA. For example, slow-growing aneurysms 
may reflect ECM synthesis mechanisms counterbalancing the ECM 
degradation mechanisms. Acceleration of aneurysm growth and rupture in 
the AAA disease course may result from this equilibrium shifting towards 
degradation. Therefore, it is encouraging that the data presented in this 
thesis suggest a period of decreased proliferative activity late in the AAA 
disease course, which may suggest that VSMCs may partially contribute to 
the proliferative signal being detected. 
Ex vivo gamma counting of whole organs, which provided definitive evidence 
of the [18F]FLT hotspots noted on the PET/CT images, revealed 160% 
greater [18F]FLT uptake in 14-day AngII AAA compared to saline control 
aortae. All the counted organs also demonstrated greater uptake of [18F]FLT 
compared to that in the saline control organs (Figure 3.29). This observation 
may be explained by the effects of AngII on widespread cell proliferation in 
the AngII-infused model of AAA. As introduced in section 1.4.1.1, AngII 
mediates growth processes and has been shown to induce the activity of 
other vasoactive factors, such as endothelin, which further confer growth-
altering effects in cells of the kidneys, lungs, and intestines, among other 
organs (Johnson et al., 1992, Wolf and Wenzel, 2004, Slice et al., 2005, 
Wang et al., 2015). Regardless of the effects of AngII in other organs, it is 
encouraging and convincing to observe such a significant increase in 
proliferative activity as measured by [18F]FLT uptake in the aneurysmal aorta 
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of the classical AngII-infused model of AAA. In addition to the abdominal 
aorta, the spleen may be another interesting region for analysis. As 
expected, [18F]FLT uptake was observed in the spleen of all animals. 
Significant differences in splenic SUVs were not observed between saline 
control and 14-day AngII AAA mice. However, in 28-day AngII AAA mice, the 
splenic SUVs showed a 33% relative difference and a slightly greater SEM. 
Further investigation of this splenic uptake in a greater number of 28-day 
AngII AAA mice is warranted to better understand if long-term AAA disease 
is associated with changes in proliferative activity in the spleen. The spleen 
is a major repository of proliferative cells, as monocytes differentiate into 
dendritic cells and macrophages in tissue healing and repair processes 
(Drutman et al., 2012); thus, [18F]FLT uptake in the spleen is expected. 
Splenic uptake of [18F]FLT was also noted by Ye et al. in atherosclerotic 
mice, although with a difference in splenic SUVs between wildtype and 
ApoE-/- mice (Ye et al., 2015). Furthermore, in male patients with AAA, 
maximal aortic diameter and spleen volume exhibit a strong positive 
correlation (Li et al., 2017); however, more data are needed to suggest that 
spleen enlargement may play a role as an indicator of AAA progression and 
rupture. The variations in splenic SUVs observed in this study are in line with 
these previous findings, indicating that further research on the association 
between splenic activity and AAA progression is warranted.  
Finally, a positive correlation was observed between ex vivo [18F]FLT uptake 
and aortic volume at 14 days. Given the limitations of this study, there was 
no evidence to suggest that aortic volume remains positively correlated 
specifically with [18F]FLT uptake in later stages of AAA development, while 
other mechanisms may contribute to changes in aortic volume with further 
AAA progression. Nonetheless, this result is important in the context of 
early-stage AAA management post-USS screening, as [18F]FLT uptake may 
provide an additional dimension of information about AAA progression: 
proliferative activity in relation to early aortic volume changes. The utility of 
this additional dimension has considerable potential in risk assessment; for 
example, a small but highly active AAA may warrant treatment, whereas an 
indolent large AAA may not. Similar to the way in which SUV thresholds of 
[18F]FDG uptake are currently implemented in the cancer field to classify 
tumour grade/aggressiveness and guide patient intervention, there may thus 
be a role for [18F]FLT uptake thresholds in AAA management. Following from 
the previous example, a patient exhibiting greater aneurysmal [18F]FLT 
uptake (and thus harbouring early-stage AAA) might benefit more from an 
anti-proliferative drug therapy, compared to a patient exhibiting lower 
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[18F]FLT uptake (and thus harbouring late-stage AAA) who would benefit 
from surgical repair. Therapy for AAA currently involves patient health 
optimisation and surgical intervention. An added layer of information may 
pave the way for trialling medical therapies as opposed to implementing 
surgery-only options based on physical aneurysm characteristics. However, 
to confirm the correlation between [18F]FLT uptake in the abdominal aorta 
and AAA severity, further longitudinal preclinical investigations of 
aneurysmal [18F]FLT uptake and its associations with aortic size at baseline, 
14 days, and 28 days in the AngII AAA model are needed, a key limiting 
aspect in the current study due to the high rates of mortality, non-response 
to AngII, and failure of intravenous radiotracer administration, as well as the 
significantly high costs of the AngII AAA mouse model. Using the same 
cohort of mice from study initiation (i.e. day of mini-pump implantation) to 
completion (i.e. day 28 of AngII infusion) would yield robust results, although 
large numbers of animals would be needed to mitigate the aforementioned 
challenges. In terms of clinical research, a large-scale analysis of patient 
data to precisely determine the relationship between aortic sizes based on 
USS screening and [18F]FLT uptake on PET would facilitate a clearer 
understanding of whether [18F]FLT SUVs might be used as informative 
indicators of size and/or AAA stage. 
4.4  PET image analysis 
It is worth noting here that the abdominal aorta and spleen are located in 
close proximity to the urinary bladder and kidneys; the two latter organs 
readily take up [18F]FLT (as all [18F]-based radiotracers are renally excreted), 
which consequently raises the possibility of partial volume effects due to 
signal spill-over into the aortic ROI. Moreover, the combination of the PET 
scanner’s spatial resolution (1.55 mm) (Sanchez et al., 2013) and diameter 
of the aneurysmal aorta (1.5–3 mm) made it difficult to definitively study 
[18F]FLT uptake within specific regions of the aortic wall. Nonetheless, to 
validate that the PET/CT signal was indeed originating from the aortic wall, 
ex vivo [18F]FLT gamma counting of whole aortae was performed following 
PET scanning, and the [18F]FLT PET/CT and 3D USS datasets were 
manually co-registered. To mitigate the risk of introducing significant partial 
volume effects in the image analysis results, SUVmax was the parameter of 
choice when reporting PET data in presentations or publications, for 
example. The SUVmax is prone to being affected by image noise, whilst 
SUVmean has high inter-observer variability (Büyükdereli et al., 2016); 
therefore, applying a percentage threshold of the maximum voxel values 
122 
within preselected ROIs is an approach that may help exclude regions of low 
radiotracer uptake. Determining optimal quantification metrics to assess PET 
images of AAA is an ongoing effort (Akerele et al., 2020).  
A pilot investigation of the effects of applying different SUV thresholds and 
ROI definitions on the resultant SUVs in the present study revealed that the 
SUVmean, SUV40, SUV50, SUV90, and SUVmax of abdominal aortic uptake of 
[18F]FLT in both saline controls and AngII AAA mice were significantly 
different between fixed-size and manually drawn ROIs; meanwhile, the 
SUV70 was not significantly different between the two types of ROIs. A 
potential explanation of these findings may lie in the presumption that 
applying a 70% SUV threshold may be an optimal balance between the 
SUVmax, which is predominantly affected by noise, and SUVmean, which is 
predominantly affected by partial volume effects in a given ROI. 
Furthermore, these findings are in line with supporting evidence to suggest 
that applying threshold values of 70–75% may yield consistent quantitative 
outcomes of lesion uptake throughout a longitudinal study period, regardless 
of changes in lesion morphology (Krak et al., 2005). However, conversely, 
other studies have found that thresholding values of 40–43% may be 
adequate to segment lesions (Ford et al., 2006, Sher et al., 2016), 
implicating the need for further studies to achieve conclusive results of 
optimal thresholds. In the present study, the resultant SUVs corresponding 
to the manually drawn ROIs showed less variability compared to those 
corresponding to the fixed-size ROIs, which may have been attributed to the 
fact that the manually drawn ROIs were generated uniquely to each dataset 
that i) avoided the edges of the region of uptake to minimise partial volume 
effects, ii) were in accordance with the morphology of the aneurysms, and iii) 
could be adapted to individual differences in the anatomy. On the other 
hand, the fixed-size ROIs did not account for these factors, as they were 
simply sized according to the maximum aortic diameter acquired in the study 
model without individual considerations of ROI edges, leading to more 
variable resultant SUVs, because of the included voxels being independent 
of the lesion size and shape. In addition, implementing fixed-size ROIs was 
significantly more time-efficient and a more objective approach than 
manually drawing ROIs. As a result, future research on ROI definitions will 
need to resolve the issues that manually drawn ROIs are currently able to 
overcome.  
The overall findings are likely to have clinical implications when analysing 
large datasets and images containing regions of low uptake; in these cases, 
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it may be more beneficial to determine the SUV70 for consistency between 
different approaches of ROI generation. Delineating lesions using fixed-size 
ROIs is a simple, relatively quick, semi-automatic approach that is correlated 
with less sensitivity to partial volume effects. Meanwhile, a potential problem 
associated with using the fixed-size method in the context of AAA is the 
variability in the size and shape of aneurysms across different patients, 
reflected in the variability in radiotracer uptake, in turn leading to differences 
in the proportion of an aneurysm contained within a fixed-size ROI. This may 
particularly cause difficulties in longitudinal studies, wherein the size and 
shape of aneurysms are likely to alter over time. Although studies have been 
conducted to determine the size of a fixed-size ROI that would result in the 
least deviation from the actual radioactivity concentration (Nahmias and 
Wahl, 2008, Weber et al., 2015), these issues are minimised when 
implementing manually drawn ROIs.  
4.5 Anti-proliferative treatment for AAA 
Currently, no targeted pharmacological treatments for AAA are used in 
clinical practice; EVAR and OAR remain the mainstay of current 
interventions. The evidence of a period of active cell proliferation in the AngII 
AAA model is encouraging to test the effectiveness of anti-proliferative 
therapies in targeting AAA, which was the original motivation for 
investigating cell proliferation in the present study. Imatinib, also known as 
Gleevec®, is a tyrosine kinase inhibitor that is suggested to play a role in the 
inhibition of T lymphocyte proliferation and mast cell activation, both of which 
contribute to AAA development (Juurikivi et al., 2005, Seggewiss et al., 
2005, Shimizu et al., 2006, Sun et al., 2007). Imatinib has also been 
demonstrated to inhibit endothelial cell population growth, platelet-derived 
growth factor (PDGF) receptor activation, and the proliferation and migration 
of VSMCs, which are key players in AAA formation (Vrekoussis et al., 2006, 
Hacker et al., 2007, Ballinger et al., 2010). Based on these findings, imatinib 
as a treatment for AAA was tested by Vorkapic et al. using the AngII AAA 
murine model and human samples of AAA tissue. They demonstrated that 
imatinib attenuates AAA development by inhibiting the recruitment of T 
lymphocytes and mast cells and SMC-mediated processes (Vorkapic et al., 
2016). Drawing inspiration from this study but with a focus on early changes 
in cell proliferation post-treatment, the present pilot study demonstrated 
increased abdominal aortic [18F]FLT uptake in the AngII AAA model at 14 
days, which was then shown to decrease by 89% following only 3 doses of 
imatinib. An important limitation in the present results was the small sample 
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size; the high rate of deaths immediately after radiotracer injection and 
unusually high bone uptake in this cohort led to the suspicion that the 
radiotracer stock might have been supplied from an unstable batch, resulting 
in unintended interactions once injected. Anti-proliferative treatments, such 
as imatinib, might be a promising therapeutic option for early-stage AAA, 
although further preclinical studies with larger numbers are needed to justify 
and validate this. The fundamental aim of treating AAA is to prevent aortic 
rupture and its corresponding high rate of mortality. Given that the only 
treatments currently offered (EVAR and OAR) are plagued with considerable 
postoperative complications, such as the need for re-repair, occurrence of 
endoleaks, and postoperative morbidity and mortality, there is a precedence 
for identifying less invasive means to treat AAA. In this context, a prevailing 
issue with the prospect of imatinib as a treatment option for patients with 
AAA is the reduced ability to detect AAA in patients during the early, 
proliferative growth stage of the disease. Furthermore, as a 
chemotherapeutic agent, imatinib is likely to confer toxic effects on non-
aneurysmal proliferative cells, such as cells of the spleen and bone marrow, 
and also lead to adverse side effects, such as gastrointestinal disruption and 
hair loss. Nevertheless, the present findings provide further validation of the 
increased [18F]FLT signal observed at the 14-day time point in this model 
and demonstrate that [18F]FLT PET/CT can be used to detect changes in cell 
proliferation that are induced by short-term anti-proliferative treatment. 
Regardless of whether imatinib becomes a treatment option for AAA, it may 
be beneficial to adopt oncologic clinical approaches, such as using [18F]FLT 
PET/CT as a tool to stratify patients in the pursuit of personalised medicine 
and to evaluate the response to a less toxic equivalent of chemotherapy. 
It is important to recognise that proliferation in AAA may not be solely 
detrimental, and thus, the use of anti-proliferative agents may not be a ‘one-
off’ treatment option. As outlined in sections 1.3.5 and 4.3, accumulating 
evidence suggests that there is an active proliferative phase early in the AAA 
disease course. Halting this activity via anti-proliferative agents may indeed 
slow down or delay AAA progression. However, when also considering other 
factors contributing to aortic wall stress, if the aortic wall integrity has already 
been compromised, then it may be beneficial to leave proliferation 
unhindered in an attempt to stabilise the aortic wall and prevent further 
degradation. Thus, anti-proliferative therapy could ideally be determined on 
a patient-to-patient basis, according to AAA progression and aortic wall 
stability in those who show abdominal aortic [18F]FLT uptake on PET 
imaging. With insignificant aortic expansion and low wall stress, anti-
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proliferative therapy may not be as effective because the proliferative activity 
may protect the wall from further degradation. However, in cases of rapid 
aortic expansion and increased wall stress, patients may benefit from anti-
proliferative therapy to inhibit further wall weakening and degradation 
leading to rupture. In this way, with an imminent need for pharmacological 
treatment options for AAA, patient-specific therapy decisions incorporating 
different biomarkers hold significant potential. 
4.6 Future directions 
AAA remains a significant cause of mortality in adults as a result of aortic 
rupture. USS provides information regarding anatomical changes in AAA 
size and shape; however, there remain gaps in our knowledge of the 
molecular changes that precede physical manifestation of the disease and in 
our ability to visualise these pathological mechanisms at the molecular level. 
A better understanding of these functional changes in early-stage AAA may 
help stratify patients based on rupture risk early in the disease course and 
guide appropriate treatment selection. Despite the large number of AAA 
studies conducted, our knowledge of AAA pathobiology is incomplete, and 
there remains a lack of concrete data to translate preclinical findings to 
clinical practice. Although several risk factors and potential contributors to 
the disease process have been identified, these are not yet sufficiently 
predictive when applied to individual patients.  
As we move forward, a shift away from aortic diameter as the main indicator 
of AAA repair is perhaps required. There is a need to investigate the 
feasibility of alternative markers of AAA rupture that may be more reliable, 
such as circulating biomarkers, MRI findings, and haemodynamic 
parameters. In this context, the pathophysiology of AAA in humans remains 
partially clear and represents an ever-growing area in cardiovascular 
research. This is largely due to the fact that studies of AAA in humans are 
predominantly limited to using late-stage aortic tissue obtained during 
surgery, owing to the asymptomatic presentation of early-stage AAA. A wide 
array of imaging techniques have been and are currently being explored for 
applications in AAA diagnosis and management. Anatomical modalities have 
reigned over the past few decades in both preclinical and clinical imaging of 
AAA. Meanwhile, functional imaging is gaining increasing importance for 
AAA, and several new functional imaging studies of AAA are anticipated in 
forthcoming years. Non-invasive molecular imaging of AAA is significantly 
promising for clinical translation, particularly in facilitating patient risk 
stratification. It is important to note that anatomical and molecular imaging 
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techniques are not competitive; rather, they are complementary in their 
usefulness for AAA management. Thus, non-invasive imaging modalities 
such as PET offer a means to detect and evaluate components of potentially 
contributing pathways in patients to better understand the development of 
AAA beyond morphological features. The overall findings of the present 
study open up several avenues for further research to elucidate the 
pathobiology of AAA beyond the scope of this thesis.  
4.6.1 Considerations of the AngII AAA mouse model 
Aortic tissues cannot be obtained from patients at early stages of the AAA 
disease course; this creates an evident need for appropriate laboratory 
models to study early-stage mechanisms. The evidence of heightened cell 
proliferation in the 14-day AngII AAA mouse model is encouraging to 
investigate changes in the proliferative activity at more time points in the 
disease course using [18F]FLT PET/CT. With less stringent economic 
restrictions, it would be ideal to image mice of this model at serial time 
points, i.e. weekly, to track even slight fluctuations in cell proliferation until 
the aneurysm ruptures. Moreover, the cellular composition of early-stage 
AAA remains largely unclear owing to the lack of access to early-stage 
human tissue. Histological staining of early-stage AAA tissues from mice 
could be performed using markers such as alpha-smooth muscle actin to 
identify SMCs, FLK1 to identify endothelial cells, collagen, and macrophage 
markers (e.g., CD45, CD68). The use of mice also facilitates genetic studies, 
wherein the effects of knocking out or overexpressing a gene can be 
investigated; some candidate genes to study in the setting of early-stage 
AAA to further elucidate the cellular composition include those specific for 
SMCs, such as SM22α; MMPs; collagen, such as COL3A1; or elastin, such 
as ELN (Lin et al., 2018, Quintana and Taylor, 2019).   
Although it is clear that preclinical models are invaluable in the progression 
to clinical studies, whether animal models of AAA accurately represent 
human AAA remains a point of discussion. With the widespread use of 
rodent models of AAA, several pathophysiological characteristics of human 
AAA are mimicked, such as ECM degradation, SMC loss, inflammation, 
calcification, and neovascularisation (Daugherty and Cassis, 2004). 
However, when translating the findings of this study to clinical practice, it is 
important to consider that a notable difference between AAA in humans and 
AAA in the AngII mouse model is the localisation of the disease in the infra-
renal and suprarenal regions of the abdominal aorta, respectively. The 
suprarenal localisation of AAA is consistently observed in the AngII AAA 
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murine model (Cao et al., 2010, Rateri et al., 2011, Lu et al., 2015). 
Meanwhile, regional differences in collagen and elastin content are proposed 
to contribute to the infra-renal localisation of AAA in humans (Halloran et al., 
1995). These points highlight the importance of considering the 
distinguishing characteristics of different models and species when tailoring 
AAA investigations to a specific aim. However, because of the lack of data 
regarding AAA formation in humans due to research being limited to late-
stage tissues from patients with confirmed AAA, it remains difficult to assess 
the comparability of molecular mechanisms between animal models and 
humans. 
Whilst the findings of this study are encouraging, it is important to 
acknowledge that cell proliferation in patients with AAA likely occurs at a 
much slower rate than that observed in mouse models of 14-day AngII-
induced AAA. This is based on the reported mean rate of AAA growth 
amongst patients included in the UK Small Aneurysm Trial: 2.6 mm/year 
(Brady et al., 2004). Another study of AAA growth rates in the Chinese 
population found that the mean growth rates are 2.8 mm/year in patients 
with small AAA (aortic diameters 30–49 mm) and 7.5 mm/year in patients 
with large AAA (aortic diameters ≥50 mm) (Huang et al., 2019). The typical 
spatial resolutions of clinical PET scanners (4 mm) may be insufficient to 
detect slight changes in [18F]FLT uptake based on slow changes in cell 
proliferation, like that reported in small AAA (Khalil et al., 2011). Therefore, 
[18F]FLT PET/CT shows greater potential in stratifying patients, guiding 
therapeutic trials, and aiding the prediction of AAA-targeted drug response 
after AAA has been diagnosed, rather than in initial disease detection.  
4.6.2 Future studies of calcification 
Identifying key pathways in the pathogenesis of AAA warrants the 
application of additional radiotracers to visualise and quantify other 
contributing factors. The role of calcification in AAA formation is one active 
area of research. Calcification, which entails calcium phosphate crystal 
deposition in the medial vessel wall layer, contributes to mechanical 
stiffening of the vessel wall and decreased vascular compliance (Wu et al., 
2013). Through these structural changes, calcification has been 
demonstrated to contribute to AAA rupture risk and is increased in patients 
who exhibit AAA symptoms (Buijs et al., 2013, O'Leary et al., 2015, 
Chowdhury et al., 2018, Forsythe et al., 2018). Furthermore, apoptosis—as 
reported in late-stage AAA—involves the production of apoptotic bodies, 
which play a role in promoting calcification in AAA (Proudfoot et al., 2000). 
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CT is a useful tool to generate images with detailed anatomical information, 
particularly of hard tissues such as bone. Thus, calcification is an ideal target 
for CT imaging of AAA, as evidenced by the use of calcium scoring in the 
clinic to indicate the narrowing or blockage of coronary arteries due to 
plaque build-up, which in turn helps assess the severity of coronary artery 
disease. A retrospective study of patients with TAA or AAA who underwent 
CT-based calcium scoring revealed that macrocalcification is correlated with 
greater cardiac and all-cause mortality (Chowdhury et al., 2018). 
Furthermore, vascular calcification is enhanced in symptomatic AAA and 
augments AAA rupture risk (Buijs et al., 2013, O'Leary et al., 2015). The 
most convincing evidence of calcification in AAA is reflected in the SoFIA3 
trial, the findings of which suggest that [18F]NaF PET/CT is an effective tool 
to identify AAA disease activity in patients, based on the localisation of the 
radiotracer in regions of microcalcification, which in turn, is a susceptibility 
marker of aneurysm expansion and rupture early after AAA formation 
(Forsythe et al., 2018). These findings collectively suggest that calcification 
can be used as a prognostic marker in patients with AAA to help stratify 
high-risk patients for risk-reducing interventions. It is then also worth 
considering the addition of a vascular contrast-enhanced CT or CTA scan, 
which would yield more detailed anatomical information than plain CT alone, 
following [18F]FLT PET/CT. This combination would offer insight into two key 
molecular processes that contribute to the AAA disease course (i.e. cell 
proliferation and calcification), thus conferring a more comprehensive 
assessment of patient prognosis. Additionally, it would be beneficial to 
perform [18F]NaF PET/CT of mice with AAA to acquire data that could serve 
as the preclinical version of the SoFIA3 trial. Preclinical data of [18F]NaF 
uptake in AAA have not yet been published, but a study using animal models 
would be useful to further elucidate the timing of microcalcification in AAA 
formation and progression.  
4.6.3 Prospective studies based on genetic pathways 
[18F]FDG, [18F]NaF, and [18F]FLT are some commonly used radiotracers in 
the clinic for various diseases, largely due to their ease of access and 
availability. In addition to the array of radiotracers used to investigate AAA 
as outlined in Table 1.2, there is scope for the development and testing of 
radiotracers related to pathways of genes identified to play a role in AAA 
formation and progression. For example, the Arg95 genetic variant of factor 
XIII-B is associated with an increased risk of AAA (Macrae et al., 2014), 
suggesting the role of platelets and coagulation factors in AAA 
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pathogenesis, which represent an important field of study. Radiotracers that 
are selective for coagulation factors may prove to be useful in elucidating 
AAA pathogenesis, much like the radiotracer [18F]ENC2015, which is specific 
for factor XIIIa and has been used to investigate arterial thrombi in rats 
(Andrews et al., 2019). The rs6511720 single-nucleotide polymorphism in 
the low-density lipoprotein receptor gene has also been shown to be a risk 
factor of AAA, implicating the correlation between AAA and cholesterol 
homeostasis (Bradley et al., 2013); thus, cholesterol-targeted radiotracers 
may be informative in the context of AAA. Furthermore, a meta-genome-
wide association study by Jones et al. confirmed the roles of several risk loci 
in the following genes that seem to exhibit specificity for AAA than for other 
cardiovascular diseases: BCAR3, SORT1, NOTCH2, TDRD10, UBE2W, 
CDKN2B-AS1/ANRIL, LRP1, NAB2, FGF9, and PLTP (Jones et al., 2017). 
The specificities of these genes are promising for the development of 
radiotracers that specially target AAA-associated gene transcription. For 
example, BCAR3 is known to play a role in the development of anti-
oestrogen resistance in oestrogen receptor (ER)-positive breast cancer 
(Wallez et al., 2014). The radiotracer 16a-[18F]-fluoro-17b-estradiol 
([18F]FES) has recently been demonstrated to be an effective PET 
radiotracer to detect ER-positive breast cancer (Liu et al., 2019); thus, based 
on the genetic link, [18F]FES may also have PET imaging applications in 
patients with AAA harbouring upregulated BCAR3 expression. Moreover, 
determining the correlation between the expression of these susceptibility 
genes and [18F]FLT uptake in AAA may be informative. For example, 
CDKN2B-AS1/ANRIL is a tumour suppressor that is also consistently 
associated with cardiovascular diseases and has been shown to influence 
cell proliferation, senescence, and apoptosis via epigenetic mechanisms 
(Congrains et al., 2013). A patient that exhibits both upregulated CDKN2B-
AS1/ANRIL expression and increased [18F]FLT uptake may have a high-risk 
AAA that would benefit from immediate therapeutic intervention as opposed 
to a patient with only one of these risk factors.  
4.6.4 Potential studies related to angiogenic and immune 
mechanisms in AAA 
Angiogenesis is another mechanistic area that provides a basis for PET 
imaging targets. AAA is associated with a marked angiogenic response and 
enhanced medial neovascularisation (Thompson et al., 1996, Choke et al., 
2006). Various pro-angiogenic factors have been implicated in the formation 
and progression of AAA. In particular, vascular endothelial growth factor 
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(VEGF) has been shown to promote AngII-induced AAA formation in ApoE-/- 
mice (Kobayashi et al., 2002). A VEGF-specific PET radiotracer, 89Zr-
ranibizumab, has been investigated in human xenograft tumour models and 
shown to correlate with VEGF status and angiogenesis (Nagengast et al., 
2011). In addition, 64Cu-DOTA-VEGF121 has been demonstrated to reveal 
VEGF receptor levels in small-animal tumour models (Chen et al., 2009). 
Another pro-angiogenic factor that has been reported to contribute to AAA is 
PDGF, the receptors of which are strongly expressed in VSMCs in AAA, and 
reducing PDGF receptor activation via imatinib has been shown to attenuate 
AAA formation (Kanazawa et al., 2005, Vorkapic et al., 2016). Meanwhile, 
the tracer 111In-DOTA-Z09591 has been demonstrated to accumulate in 
regions with increased levels of PDGF receptor expression (Tolmachev et 
al., 2014). Radiotracers specific for the microRNA-195 family may also be 
useful to study AAA development, as microRNA-195, which modulates 
angiogenesis, has been demonstrated to regulate the aortic ECM in murine 
AAA (Zampetaki et al., 2014). Exploring the usefulness of angiogenesis-
specific tracers that have been validated in other disease models in 
visualising sites of angiogenesis in AAA models may be interesting avenues 
in preclinical research.  
Immune cells, such as lymphocytes, cytokines, and antigen-presenting cells 
are observed in AAA (Kuivaniemi et al., 2008); however, no dedicated PET 
studies have been conducted previously to specifically investigate these cell 
types in AAA. The spleen plays a key role in immunologic functions, being a 
site of immune cell subsets (Lewis et al., 2019). Thus, the variations in 
splenic uptake of [18F]FLT demonstrated in this study may correspond to the 
distinct varying roles of immune cells at different stages of the AAA disease 
course. The radiotracer 64Cu-DOTA-ipilimumab has been investigated in 
models of non-small cell lung cancer (Ehlerding et al., 2017). This tracer 
targets cytotoxic T lymphocyte-associated protein 4, the levels of which are 
reported to be increased in AAA (Sakthivel et al., 2007), thus making it a 
potential biomarker for AAA. Additionally, 68Ga-pentixafor has been studied 
in atherosclerotic plaques to image the cytokine receptor CXCR4, which may 
also be informative in AAA (Hyafil et al., 2017). Immune mechanisms thus 
remain an active area of AAA research.  
4.6.5 Clinical translation 
It is well established that PET can be used to evaluate treatment response, 
in addition to its uses in disease management. Its ability to provide detailed 
longitudinal information at the molecular level makes it ideal to stratify 
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patients according to disease risk. In the context of AAA, [18F]FLT PET may 
be useful as a management indicator in high-risk patients who have not yet 
developed AAA. For example, if a patient exhibits many risk factors (such as 
a man aged 65 years or older with heavy smoking habits and a familial 
history of AAA) but does not yet physically manifest AAA, then [18F]FLT PET 
may be used as a tool to determine if there is evidence of abnormal cell 
proliferation based on the radiotracer’s uptake in the aortic region. Cases of 
positive [18F]FLT uptake suggest a role for prophylactic interventions, such 
as early placement of anti-proliferative drug-eluting aortic stents. 
Additionally, [18F]FLT may be utilised as a predictor of prognosis in patients 
who are already diagnosed with AAA. For example, if a patient with USS-
established AAA does not reveal [18F]FLT uptake on PET, then he/she may 
be stratified to a more advanced disease stage, possibly requiring surgical 
intervention. Conversely, if a patient with established AAA reveals [18F]FLT 
uptake on PET, then he/she may be stratified with an earlier disease stage, 
requiring a less surgically intensive intervention. In this way, [18F]FLT PET 
may then play a more significant role in personalised medicine to aid 
disease risk stratification as opposed to population-level screening.  
The clinical translation of radionuclide-based tracers is crucial to maximally 
benefit patients with AAA. PET imaging is immensely useful in comparison 
to USS and optical imaging methods; however, much of the preclinical PET 
research on AAA never proceeds to the clinic. This is largely due to hurdles 
such as the overwhelming cost of introduction in the clinic, a lack of 
understanding between preclinical scientists and clinicians, and long-
standing regulations. Cooperative partnerships amongst researchers, 
clinicians, and pharmaceutical chemists are imperative to identify and verify 
novel imaging markers and more clinically applicable preclinical models, as 
well as to generate and test tracers, followed by smooth transition for 
application to patient management. Ultimately, the optimal imaging marker 
will reveal key aspects of AAA formation in humans, be used for patient risk 
stratification, and help assess treatment efficacy in novel clinical trials. 
4.7 Conclusion 
Overall, in this thesis, [18F]FLT PET/CT was demonstrated to be a feasible 
modality to visualise and quantify cell proliferation in a classical preclinical 
model of AAA, the AngII AAA murine model. This method shows great 
potential as a clinical risk stratification biomarker and in monitoring 
pharmacological treatment response in patients with AAA. Future studies of 
PET image analysis would benefit all clinical fields by establishing 
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quantitative metrics that could yield reliable and consistent results across 
varying ROI definitions. Prospective studies of PET in the context of AAA 
would benefit from focussing on the development of PET radiotracers that 
target alternative molecular pathways involved in the development of AAA 
disease before its physical manifestation. Until then, 65 years on, two issues 
remain unresolved: Einstein’s unified field theory and how best to manage 
early-stage AAA.  
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Appendix A 
Copies of all conference posters associated with this thesis are provided here. 
 
 
Figure A.1 Poster for the European Molecular Imaging Meeting 2018 
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Figure A.2 Poster for the European Molecular Imaging Meeting 2018 
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Figure A.3 ePoster contents for the Annual Congress of the European 
Association of Nuclear Medicine 2018 
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Appendix B 
The results of non-parametric statistical tests are presented here. The Kruskal–
Wallis test was used for the data presented in Figures B.1, B.5, B.6, B.7, B.8, 
and B.9. The Mann–Whitney U test was used for the data presented in Figures 
B.2, B.3, and B.4. All significant results according to parametric tests remain 
statistically significant following non-parametric analysis.  
 
 
Figure B.1 PPE and AngII AAA tissue reveal the greatest proportions of 
Ki67-positive nuclei. Proportion of Ki67-positive nuclei in saline controls (n=3) 
and in the AngII (n=6), PPE (n=7), and CaCl2 (n=4) AAA models. * p<0.05, ns: 
not significant on Kruskal–Wallis test. 
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Figure B.2 Aortic volumes and diameters are larger in the AngII AAA 
model than in saline controls. Aortic volumes and diameters in 14-day AngII 
AAA (n=9) vs. saline control aortae (n=4). * p<0.05, ** p<0.01 on Mann–
Whitney U test. 
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Figure B.3 [18F]FLT uptake in the abdominal aorta was greater in the 14-
day AngII AAA model than in saline controls. Absolute values of SUVmax and 
SUVmean representing 14-day [18F]FLT uptake in abdominal aortic ROIs 80–90 
min post-radiotracer injection in 14-day saline controls (n=5) and the 14-day 
AngII AAA model (n=5). ** p<0.01 on Mann–Whitney U test. 
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Figure B.4 Ex vivo [18F]FLT uptake in the abdominal aorta was greater in 
the 14-day AngII AAA model than in 14-day saline controls. Decay-
corrected ex vivo [18F]FLT counts per mass units. Uptake in the spleen and 
abdominal aorta normalised to uptake in the heart in the 14-day AngII AAA 
model (n=9) and 14-day saline controls (n=4). * p<0.05 on Mann–Whitney U 
test. 
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Figure B.5 TK-1 expression was the greatest in 14-day AngII AAA. 
Quantitative analysis wherein TK-1 band intensity was normalised to β-actin 
band intensity. * p<0.05, ns: not significant on Kruskal–Wallis test. 
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Figure B.6 ENT-1 expression was the greatest in 14-day AngII AAA. 
Quantitative analysis wherein ENT-1 band intensity was normalised to β-actin 
band intensity. * p<0.05, ns: not significant on Kruskal–Wallis test. 
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Figure B.7 ENT-2 expression was the greatest in 14-day AngII AAA. 
Quantitative analysis wherein ENT-2 band intensity was normalised to β-actin 
band intensity. * p<0.05, ns: not significant on Kruskal–Wallis test. 
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Figure B.8 CNT-1 expression was the greatest in 14-day AngII AAA. 
Quantitative analysis wherein CNT-1 band intensity was normalised to β-actin 
band intensity. * p<0.05, ns: not significant on Kruskal–Wallis test. 
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Figure B.9 CNT-3 expression was the greatest in 14-day AngII AAA. 
Quantitative analysis wherein CNT-3 band intensity was normalised to β-actin 
band intensity. * p<0.05, ns: not significant on Kruskal–Wallis test. 
